annual report p e n n n v n p r n e r cancer modern care helps advanced analytics enable us roche expanding colla b effective treatments create wealth new data insights orations combining available previously innovative opportunities across strengths unique tools therapies allow woman entire product lifecycle rd partners elevate personalised cover picture carry value chain ultimately improve healthcare new level many life see back cover outcomes patients patientskeith terry genentech usa emotional hire medical doctor talent scout genentech family friendsand dwell south san francisco work closely negative taught stay moment product development neuroscience team ironically times big win hiring senior medical experienced relapse felt fatigued director ocrevus medication currently effort breathe difficult imagine use treat multiple sclerosis ms level fatigue experienced emotional hire illness really increased capacity empathy ill diagnosed multiple sclerosis years ago age experiencing extreme overall many positives fatigue loss motor function hands met many amazing people ms time numbness torso experience active member arms believe ms year actually ms society led support group individuals diagnosed prior ignored ms five years also participated fatigue thought must happening local ms walk community try get getting older getting enough vitamins used exercise every day capacity seems power felt fatigued major really help also good diet event occurred could ignore important challenges though motor function hands definitely decreased happened leading hiring initiative also shortterm memory affected bank writing white board kept dropping pen felt really weak left arm others ms would sayget involved hand thought heart attack great things going ms community also ended emergency room heart ignore symptoms including depression condition sent home kept feeling worse common symptom often ignored worse visited four different emergency medical depression related ms used good centres mri showed lesions spinal days bad days illness however since cord brain multiple sclerosis started taking ocrevus year half ago almost days good high level diagnosis made focus important energy thankful thingsdeveloping enhancing relationshipsinnovation dna always worked across disciplines geographies drive scientific discovery redefine possible improve patients lives working understanding diseases also world leader vitro diagnostics differ molecular level develop business track record allows us build lasting new tests medicines prevent diagnose meaningful partnerships across world treat diseases bring patients research academia public healthcare institutions need combined strengths diagnostics pharmaceuticals personalised founding families continue hold majority healthcare strategy aims fit right treatment voting stake company stability allows right patient tradition sustainable thinking learn setbacks focus lasting value patients worlds largest biotech company develop society remain dedicated highest breakthrough medicines improving standard standards quality safety integrity legacy care across oncology immunology infectious based respect individual well diseases ophthalmology neuroscience communities world live employees worldwide north america europe employees employees genentech south san francisco us basel kaiseraugst rotkreuz switzerland roche diagnostics indianapolis us mannheim penzberg germany asia employees chugai tokyo japan shanghai suzhou china latin america employees africa australianew zealand employees employees research development sites manufacturing sites pharmaceuticals pharmaceuticals diagnostics worldwide diagnostics worldwide roche group headquarters manufacturing sites pharmaceuticals diagnostics largest sites based number employees sales sites pharmaceuticals diagnostics research development sites pharmaceuticals diagnostics number employees expressed fulltime equivalentshighlights supporting continued growth progressing alzheimers diagnosis chf billion salesocrevus two forms fda breakthrough device designation elecsys assays ms successful new product launch roche support early improved diagnosis alzheimers disease read read treating rare blood disorder improving access healthcare hemlibra indicated haemophilia patients roche takes lead role scaleup city cancer us challenge change global landscape cancer care read read fighting influenza infections contributing sustainability xofluzafirst singledose oral medicine treat influenza roche ranked sustainable healthcare company approved us dow jones sustainability indices tenth successive year read read key figures chf million chf million group sales rd core investments chf million roche medicines core operating profit model list essential medicines chf million patients dividend treated roche medicines growth rates report constant exchange rates cer average contents overview strategy chairmans shareholder letter interview ceo roche group business performance group performance diagnostics performance pharmaceuticals performance science innovation data insights better informed decisions harnessing frontline scientific technologies access healthcare digital platforms support patients continuing fight hivaids people increasing agility drive manage change nurturing attracting talent environment decreasing energy consumption reducing greenhouse gas emissions community engagement paths strong societies unlocking potentials growing talents integrity business ensuring operational resilience partnerships lasting future corporate governance board directors corporate executive committee remuneration report principles remuneration components reporting approach roche committed transparent reporting endeavour drive economic social environmental performance diligence financial performance reporting scope boundaries emerging sustainability risks opportunities financial nonfinancial reporting consists provided risk management web annual report finance report online report contains annual financial statements consolidated group risk report covers consolidated financial statements nonfinancial material risks discussed annually performance indicators covers regions corporate executive committee reviewed divisions january december audit committee board directors financial reporting scope defined outlined board directors effectiveness group risk finance report significant management process regularly monitored group changes scope compared risk advisory team overall process reviewed externally appropriate risk management reporting accordance latest embedded levels group pharmaceuticals gri guidelines diagnostics divisions global functions conduct followed gri g guidelines global formal risk assessment process least year reporting initiative since using gri must develop risk plans material risks guidelines disclose critical impacts activities environment society economy group risk advisory facilitates risk discussions reporting period transitioned support business many specialist areas newly introduced gri standards based security well compliance sustainability key concepts disclosures gri g training sessions platforms established guidelines report accordance standards help employees manage monitor mitigate risks core level also go beyond requirements appropriately core level number indicators read corporate governance risk management risk management policy sets roches approach external assurance identifying analysing managing reporting current annual report includes independent internal external risks opportunities also assurance report nonfinancial reporting identify business sustainability risks opportunities prepared pricewaterhousecoopers ag annual basis integrate existing group risk management process information see independent assurance report reporting approach roche material topics tier fundamental drivers ability deliver core purpose long term rd pipeline strategy personalised healthcare employee engagement talent retention growth strategy emerging developed markets product portfolio strategy patent policies leadership commitments materiality tier major influencing factors business accordance gri standards conducted success short medium term first materiality analysis corporate level pricing gathered input feedback various disease awareness treatment education internal external sources conferences compliance conducting regular interviews oneonone drug efficacy safety counterfeiting discussions key stakeholders results supply chain management since regularly vetted ongoing stakeholder biosimilar safety research across key markets stakeholder groups sustainable healthcare enables us include topics stakeholder groups consider important business tier additional material topics healthcare sector patient organisations executive remuneration physicians laboratory staff employees media compensationbenefits investors payers regulators governments organisational effectiveness environmental responsibility material topics screened community engagement priorities deemed key roche three tiersfirstly patient organisation support fundamental drivers ability deliver data transparency clinical trials core purpose long term secondly additional occupational accidents annually reviewed major influencing factors business success short medium term finally material topics providing three levels priority addressing material topics materiality rochecommateriality three tiers material topics reflected business priorities report content key performance indicators highlighted beginning chapter rochecomperformance well aspect boundaries according gri build concrete actions relating topics online roche annual report operational activities measure performance arrochecom defined indicators roche annual report pdf currently conducting second global rochecomarepdf materiality assessment results assessment published website roche finance report pdf inform strategy moving forward well rochecomfbepdf content annual report risk management see strategy rochecomriskmanagement commitment un sdgs global healthcare company committed supporting number united nations sustainable development goals sdgs line business strategy particular contribution un sdgs sdg aims ensuring healthy lives rochecomunsdgssustainable development goals roche history years strong commitment sustainability supporting sdg innovating patients million patients treated roche medicines billion tests conducted roche diagnostics products roche medicines model list essential medicines trustworthy partner new partnerships diagnostics new partnerships pharmaceuticals approximately businesscritical suppliers riskassessed protecting environment decrease water consumption since decrease energy consumption since improvement ecobalance since delivering continued growth group sales core operating profit sustainability leader according dow jones sustainability indices providing great workplace employee engagement rate key leadership positions held women key leaders diverse work experience world health organization growth rates report constant exchange rates cer average measured global employee opinion survey done focus people fitting treatments patients making mark distinctiveness decisionmaking excellence science accountable transparent delivery structure value stakeholders built innovation itour strategy roche strategy focus finding new medicines diagnostics help patients live longer better lives evolve practice medicine guided purpose molecular biology seamless integration patients need next pharmaceuticals diagnostics capabilities company year history diversity approaches maximise innovation advancing field medicine bringing novel longterm orientation treatments diagnostics patients patient remain core reason delivery create value stakeholders come work every day partner choice bringing significant medical benefit patients doctors payers offering great place work employees delivering sustainable positive contribution society creating topquartile total shareholder return focus fitting treatments patients investors providing right therapy group people respond best right time inhouse combination pharmaceuticals diagnostics uniquely positioned deliver personalised healthcare developing internal capabilities ultimately takes people integrity courage building strategic partnerships ready next passion make difference patients stage personalised healthcare combine insights people proud say roche multiple data sources sophisticated analytics embrace diversity cultures people drive effective efficient research allow across group inclusive encourage better therapeutic decisions patients access richness ideas approaches brings products also critical part strategy detailed access plans embedded decisionmaking principles processes business local level emphasise transparent dialogue clear accountability encourage high degree empowerment continue concentrate energies entirely prescription medicines vitro diagnostics structure built innovation autonomous rather diversify sectors like generics research development centres alliances biosimilars overthecounter medicines external partners foster diversity scientific approaches agility global geographical scale pursuit excellence science reach enables us attract talent biggest distinctiveness rests four key elements global science clusters bring diagnostics exceptionally broad deep understanding medicines quickly people need personalised healthcare taking next leveldigitalisation triggers business transformation digitalisation refers use digital technologies increasingly seen potentially rich modify existing business model life science underutilised source generate benefits two ways companies healthcare providers patients addition insights derived realworld consumers use digital technologies believed data offers prospect taking personalised harbour significant potential streamlining healthcare next level diagnosis treatment processes helping achieve superior treatment highly tailored terms effectiveness outcomes safety individuals unique condition b linking clinical trial data realworld data underlying view number recent dramatic advances biological medical developments first quality health data becoming knowledge expected provide leads available electronic form new digital capabilities targeted research efficient development processes becoming common practice include recording health data digitally example low either way evolution require partnerships cost mobile devices thereby transforming existing traditional players healthcare providers records notes images format suitable payers life sciences experts device manufacturers machine learning curating data efficiently well nontraditional entrants retailers depth data enhanced novel data types telecommunications technology companies characteristics example genetic profiles entrepreneurs venture capital investors consistent data across longer time periods second tools advanced analysis large data volumes embedding digitalisation across organisation emerging advances computing power data roche pharmaceuticals digitalisation trans handling sophisticated analysis techniques forming way medicines developed tested adopted healthcare delivered patients leverages rapidly increasing volume healthrelated data diagnostic test result explosive growth results critical development even highquality data analysed sophisticated medicines roche diagnostics interpreted particularly data accessible datadriven processes allow optimised workflows routine clinical practice captured electronic laboratories medical decisionmaking thus medical records often referred realworld data improving laboratory efficiency treatment efficacypersonalised healthcare roche data management pharmaceuticals diagnostics personalised healthcarethe next level ms progressive disease start however pursuing next level personalised healthcare ability characterise prognose individual adding third dimension roches expertise disease course realworld limited pharmaceuticals diagnostics data management introduction smartphones wearable roche rapidly expanding existing capabilities technologies carry ability continuously deploying internally externally track health three examples floodlight uses smartphone sensorbased measures large data sets allow better insights detect subtle changes cognition motor partnerships foundation medicine function develop novel measures disease inc usa specialising genetic profiling cancer progression aims empower people flatiron health curating electronic medical ms information disease records building call meaningful give healthcare professionals tools recognise data scale combine datasets progression fundamentally improve deep understanding cancer diagnostics understanding ms individualise patient care treatment look specific patterns ranges determining prevalence cancer biomarkers support manage increasingly complex data identifying potential druggable targets rapidly increasing wealth complexity insights increasingly allow us answer questions data represent formidable challenge healthcare could answered example professionals roches navify decision support small patient populations provide effective portfolio fully integrated clinical workflow intervention options cancer patients solutions clinical decision support apps helps multidisciplinary care teams navigate maze understanding disease progression ms medical information using analytics transform personalised healthcare aims improve outcomes large amounts data actionable insights patients multiple sclerosis ms means detecting disease progression earlier developing tools accelerate drug development kpmg digitalisation life sciences ey healthcarethe crosscurrents convergence deliver participatory health year strong growth dear shareholders view increasing competition biosimilars particularly encouraging note sales digitalisation permeating ever significant growth driven innovative new areas lives healthcare sector medicines ocrevus perjeta breast cancer exception severin schwan explains pages tecentriq cancer immunotherapy alecensa lung digitalisation presents tremendous opportunities cancer hemlibra haemophilia well researchbased diagnostics pharmaceuticals immuno diagnostics business thus company roche intend leverage broadly supported opportunities provide even better diagnostic decisionmaking support doctors roche one best product pipelines develop muchneeded treatments faster industry alone invested chf billion targeted way examples efforts include development leader oncology finalised transaction foundation medicine growing number neuroscience projects acquisition flatiron health united states immunology performing well last helped us improve ongoing efforts six years us food drug administration personalised healthcare granted breakthrough therapy designations fewer roches active ingredients six latest medical innovations particular alone achievement proud another reason optimistic outlook roches future ocrevus approved multiple sclerosis ms strength innovation also reflected successful product launch roches financial results roche increased sales history effective relapsing forms ms well chf billion ifrs net income rose cases patients condition steadily worsens chf billion owing positive business outset ocrevus first medicine ever performance proposing dividend approved primary progressive form ms swiss francs per share nonvoting equitychairmans shareholder letter roche security annual general meeting companies universities one recent march subject approval example influenza medicine xofluza initial nd consecutive dividend increase research compound carried japanese pharmaceuticals company shionogi also delighted nomination professor subsequently developed roche partnership dr hans clevers professor molecular genetics shionogi xofluza received fasttrack approval university medical center utrecht netherlands united states october first election board directors professor influenza treatment novel mechanism clevers outstanding scientist great expertise action almost years experience medical research focus personalised healthcare aim gratifying see sustainability sustain growth trajectory well mindset embedded levels company confident pursuing strategy systematic roche recognised group leader innovation based medical scientific progress sustainability within pharmaceuticals sustainable solutions partnerships roche well biotechnology life sciences industry index positioned future dow jones sustainability indices tenth consecutive year see commitment continue many thanks everyone worked us operating business responsibly holistically behalf patients world thank longterm perspective employees tireless efforts achievements important contribution society development offer shareholders heartfelt thanks medicines diagnostics significantly trust placed us improve peoples lives last year billion tests conducted roche analysers million patients worldwide benefited medicines roche one first companies consolidate complement research development expertise working external partners dr christoph franz worldwide partnerships chairman board directors growth rates report constant exchange rates cer average board directors roche board directors paul bulcke b e prof sir john bell b e bernard poussot c e anita hauser e dr andreas oeri representative shareholder group pooled voting rights e andr hoffmann vicechairman representative shareholder group pooled voting rights c e dr severin schwan f dr christoph franz chairman c e dr claudia suessmuth dyckerhoff b e julie brown b e prof dr richard p lifton c e peter r voser c e corporate governance sustainability committee b audit committee c remuneration committee presidiumnomination committee e nonexecutive director f executive director committee chairperson roche board directors december midst roche apprenticesboard directors roche data protection dna roche ceo severin schwan talks completely new opportunities opening digitalisation importance trust handling patient data digitalisation mean roche nothing new always part business technologiescombined expertise division always compiled clinical trial data medical sciencehave potential fundamentally basis obtaining approvals new medicines improve accelerate way research whats new longer evaluate data develop sell medicines diagnostic systems clinical trials also data clinical practice continue stand diagnostics reason data medicines also market increasing number increasingly compiled recorded electronically digital solutions alongside tangible products pharmaceuticals diagnostics divisions talking flatiron fmi experience impact business model thats right acquiring flatiron fmi different ways pharmaceuticals assessing data taken quantum leap forward terms access tointerview ceo roche group roche data oncology even companies pursue available achieve basically want work objectives independently addition anonymised data instead accessing sensitive entered large number partnerships personal data thanks powerful anonymisation companies public institutions processes data utilisation contravene data pharmaceuticals business model changed protection connection would like fundamentally still focuses development legal certainty clear regulations regarding marketing new better medicines handling data roche currently developing monitoring app people still worried data misused parkinsons disease roche breaking new technologies always generate uncertainty app business look back debate genetic engineering would prefer say selling medicines current debate concerns parkinsons disease apps associated data misuse playing along similar lines could apps concerns justified need taken companies might also develop suitable ones seriously managed important keep negativity dominating equation genetic diagnostics engineering technology banned back diagnostics undergoing sea change achievements life sciences industry business model sold instruments would possible tests customers interpreted data medicines produced biotechnology also offer clinical decision support means aggregate data systems patients benefited genetic engineering supply relevant decisionmaking gain digitalisation information doctors patients like three things first new better medicines navify tumor board building digital realworld data enable us see connections ecosystem thirdparty companies also see classical clinical trial data able dock onto provide apps gives example spot new therapeutic targets us genuinely new business model molecules identify different subgroups within patient populations consequence develop roches position data protection new medicines much specific effective concept data need protected way second medicines reaching market dna putting data protection faster design clinical trials practice clinical trials decades regularly efficiently thus accelerate approval process find government agencies hospitals finally digital decisionmaking aids help willing partner us solid make treatments targeted efficient expertise protecting patient data trust lot everyday clinical practice helping patients need take advantage lead improving healthcare roche trust gives us substantially accelerate digitalisation puts us much faster track medical advances using data volumes achieving personalised healthcarecorporate executive committee roche corporate executive committee dr stephan feldhaus head group communications dr alan hippe chief financial officer dr william pao head roche pharma research early development pred dr james h sabry global head pharma partnering dr michael varney head genentech research early development gred dr severin schwan ceo roche group daniel oday ceo roche pharmaceuticals cristina wilbur head group human resources dr michael heuer ceo roche diagnostics dr gottlieb keller general counsel member enlarged corporate executive committee roche corporate executive committee december midst roche apprenticescorporate executive committee roche business performance roche roche showed strong business performance uptake new medicines continued strong throughout year stringent quality controls ensure products provided patients meet respective production criteria strong results divisions strong growth new products characterised year based performance roche well positioned future growth group sales rose chf billion international region sales grew led core operating profit increased reflecting asiapacific latin america subregions japan strong underlying business performance core eps sales declined due government price cuts grew ifrs net income increased biosimilar competition including benefits us tax reform higher net financial income diagnostics division sales increased chf billion centralised point care sales pharmaceuticals division increased solutions main contributor led chf billion key growth drivers growth immunodiagnostics business new medicine ocrevus used treat two forms sales increased business areas regional terms multiple sclerosis ms cancer medicines growth driven asiapacific north perjeta tecentriq alecensa hemlibra treat america sales increased emea haemophilia expected strong uptake latin america japan newly introduced medicines partially offset lower sales mabtherarituxan tarceva drug approvals expedited reviews us food drug administration fda us sales increased led ocrevus perjeta granted several approvals including tecentriq lucentis europe sales affected combination avastin paclitaxel carboplatin competition biosimilars mabtherarituxan chemotherapy initial treatment people herceptin partially offset metastatic nonsquamous nonsmall cell lung strong launches new medicines ocrevus cancer nsclc egfr alk genomic tecentriq alecensa perjeta tumour aberrations mabtherarituxan forbusiness performance roche material topics covered chapter product portfolio strategy growth strategy emerging developed markets pemphigus vulgaris avastin form ovarian roche diagnostics introduced new products cancer hemlibra people haemophilia services announced key partnerships without factor viii inhibitors xofluza baloxavir marboxil treatment acute uncomplicated strategic partnership ge influenza people aged years older healthcare combine vitro diagnostics ge healthcares vivo expertise european medical agency ema approvals codevelop comarket decision support software include ocrevus ms hemlibra people solutions anchored shared digital platform haemophilia inhibitors factor viii designed also allow third parties potentially perjeta adjuvant treatment herpositive early place product companyagnostic breast cancer high risk recurrence applications china national drug administration approved navify clinical trial match navify alecensa treatment alkpositive nsclc publication search apps launched apps scan globally renowned resources fully fda granted priority review tecentriq plus integrated navify tumor board chemotherapy albuminbound paclitaxel initial firstline treatment unresectable locally viewics inc one data analytics platforms advanced metastatic triplenegative breast cancer launched first two solution applicationsviewics tnbc people whose disease expresses pdl labops viewics dx optimizationto support protein determined pdl biomarker testing better productivity decisionmaking clinical care laboratories hospitals health authorities us eu japan granted expedited reviews entrectinib cobas pro integrated solutions serum work area solution medium lower highthroughput ema granted prime designation rg laboratories launched countries accepting treatment huntingtons disease ce mark investigational oral medicine risdiplam treatment people spinal muscular atrophy outlook sales expected grow low midsingle diagnostics data management digit range constant exchange rates core earnings decision support per share targeted grow broadly line support healthcare providers need manage sales constant exchange rates roche expects evergrowing amounts data diverse sources increase dividend swiss francs growth rates report constant exchange rates cer average us food drug administration prescribing information perjeta emea europe middle east africa diagnostics division sales products services roche diagnostics supports healthcare providers transforming data actionable insights also help laboratories around world succeed increasingly complex rapidly changing healthcare environment sales diagnostics division grew strongly businesses grew respectively continued chf billion growth reported high demand reported cobas liat tests regions business areas new system molecular pointofcare testing regional growth led emea north centralised point care solutions america largest contributor divisions sales growth serum work area solutions comprising cobas dried blood spot test qualitative early immunodiagnostics clinical chemistry infant diagnosis cobas plasma separation businesses main growth drivers card quantitative viral load testing use centralised point care solutions business cobas launched improving access expanded especially asiapacific due sales hiv diagnosis remote areas growth china north america tissue diagnostics sales increased advanced cobas pro integrated solutions serum work area staining business continued strong growth solution medium lower highthroughput demand primary staining portfolio high laboratories launched countries accepting regionally growth led north america ce mark emea growth asiapacific driven china sales molecular diagnostics increased virology sales sales blood ventana dp slide scanner launched screening human papillomavirus hpv early creating highquality tissue slidebusiness performance roche north america europe middle east africa emea japan latin america asiapacific asiapacific region divisions main growth driver images offer pathologists digital image topselling product portfolios chf millions accurately reproduces would seen microscope images serve basis full menu image analysis algorithms currently development roche also launched upath cobas enterprise software universal digital pathology immunodiagnostics software application lab administrators histotechnicians pathologists enables pathologists patientcentric case viewing quick diagnosis cobas clinical chemistry diabetes care sales increased mainly driven new accuchek guide accuchek instant systems sales growth reported north america latin america asiapacific ventana advanced staining launched pilot markets new accuchek solo micropump received encouraging customer feedback enhanced positive acceptance visible integrated diabetes management solutions including cobas mysugr virology accuchek diabetes care growth rates report constant exchange rates cer average delivering medical value digital world era digital technology increasingly future menu roche image analysis algorithms able tailor medical treatments needs scanner cemarked vitro diagnostic use individuals far information captured available us research use stored analysed revealing diseases manifest patients experience october officially opened new manu day day deepening understanding molecular facturing site rd centre suzhou china science together new diagnostic tools data support future diagnostic needs china management methods bringing disruptive changes region regional headquarters singapore patient care eight existing branches across china already major healthcare provider asiapacific holistic approach digital transformation rapid population growth coupled changing extends well beyond technology addressing entire landscape highend manufacturing encouraged customer experience encompassing product us expand global manufacturing expertise portfolio resulting new ways working locally roche diagnostics transformation business well underway enabling us become leader transforming data actionable insights digital diagnostics remaining global leader decision support vitro diagnostics medical knowledge increases exponential rate healthcare providers need manage ever one largest providers realworld growing amounts data diverse sources data produce billions test results every year electronic health records doctors notes clinical total exceeded billion results trials diagnostic instruments digital technology data initiatives already underway committed delivering roche understand confident decision digital solutions servicesin addition making clinical practice happens human industryleading diagnostics portfoliothat offer medical knowledge digital medical knowledge enhanced broader customer experiences help come together seamlessly diagnostics improve lives patients around world pharmaceuticals divisions working together one roof combining profound understanding march launched ventana dp high diseases diagnostics treatment uniquely speed slide scanner digital pathology unique positioned tackle challenges vast complex traybased design enables notouch slide processing sources data working external reduced workflow errors provides reliable high partners developing new solutions make speed scanning histology slides excellent best use data enable smarter efficient image quality reliability setting new standard research development better patient care digital pathology providing foundation overallbusiness performance roche industryleading portfolio integrated diagnostic solutions grew significantly several product launches us europe early roche diagnostics ge healthcare integration imaging imaging analytics announced agreement enter strategic means product capable integrating partnership combining vitro diagnostics roches vitro diagnostic data eg biomarkers tissue ge healthcares vivo expertise codevelop pathology genomics vivo diagnostic data comarket decision support software solutions provided ge healthcare eg medical imaging anchored shared digital platform designed also together patient information allow third parties potentially place product companyagnostic applications initial focus september launch first two navify clinical oncology acute care decision support apps underlined strategy marked next step towards personalised continue develop navify decision support healthcare navify clinical trial match navify portfolio launched help multidisciplinary publication search apps scan globally renowned care teams navigate increasingly complex medical resources fully integrated navify information first commercially available tumor board apps represent start productnavify tumor boardis cloudbased navify app ecosystem apps roche software solution fundamentally changes partners third parties follow way oncology care teams prepare conduct document clinical treatment decisions viewics inc one data analytics platforms launched first two solution applications support together ge healthcare introduce better productivity decisionmaking clinical care navify tumor board v offers deeper laboratories hospitals tests per hour roche integrated core lab icl vastly expands efficiency scope quality diagnostic capabilities laboratory industryleading portfolio integrated diagnostic solutions grew significantly several product launches us europe february received fda clearance cobas factor ii factor v test cobas system providing rapid workflow aid diagnosis patients suspected thrombophilia test enables laboratories simultaneously assess factor ii factor v gene mutations single patient sample reduce handson time testing patients cobas pro integrated solutionsstarting point new generation serum work area inherited thrombophilia test expands solutionsseamlessly integrated roche integrated core lab current menu cobas system enabling labs consolidate genomics oncology microbiology virology testing onto single platform new test also complements recent ce approval cobas october viewics labops application rolled cobas coagulation analysers central customers regions asiapacific lab making roche key partner laboratories following soon viewics labops offers easytouse performing coagulation thrombophilia testing dashboards reports data customers efficient test design allows laboratories report lab hospital operations viewics dx optimization patient samplesand resultsper minutes module also features suite dashboards reports designed optimise physician ordering protocols april received k clearance premarket available us canada submission made fda cobas ctng assay use cobas systems empowering laboratories innovation direct detection chlamydia trachomatis ct efficiency andor neisseria gonorrhoeae ng dna enabling continuous access advanced symptomatic asymptomatic individuals innovative diagnostics help laboratories around cobas ctng assay helps labs handle increasing world succeed increasingly complex testing volumes highestthroughput solution rapidly changing healthcare environment currently marketbusiness performance roche july fda granted breakthrough device per hour continuous loading supplies designations elecsys amyloid csf furthermore offers simplicity automated elecsys phosphotau p csf tests maintenance calibration also features vitro diagnostic immunoassays measure broadest swa assay menu consolidated single amyloid phosphotau concentrations platform short assay incubation times low cerebrospinal fluid csf adult patients sample volume requirements cognitive impairment evaluated alzheimers disease ad causes dementia diabetes care business implementing diagnosis ad largely based clinical strategy offer integrated diabetes management symptoms including cognitive testing solutions connecting physical products including significant number patients diagnosed blood glucose meters test strips digital disease already advanced biomarkerbased solutions services july received testing expected lead greater diagnostic cemark accuchek solo micropump certainty contribute search effective began launching first markets treatment creating open ecosystem products solutions include well thirdparty solutions nextgeneration sequencing ngs portfolio signed important datasharing agreements continues grow october three new ngs novo nordisk senseonics june avenio tumor tissue analysis kits launched entered collaboration agreement care globally researchuseonly ruo kitsthe innovations telehealth solution provider avenio tumor tissue targeted kit expanded kit agreement care innovations customers based surveillance kitdetect four mutation us canada offered mysugr classes solid tumours complement ngs app allows people diabetes receive ctdna kits oncology research avenio ruo advice certified diabetes educators customers portfolio readytouse kits provides reagents also accuchek guide blood glucose software needed labs determine genomic meter test strips delivered directly characteristics solid tumours single homes dna workflow integration insulin dosage continuous december launched cobas pro integrated glucose monitoring data digital solutions solutions laboratories medium high including mysugr help create insights based throughput serum work area swa testing data personalised solutions aim improve new generation swa solutions offers high level therapy outcomes patients thereby benefiting efficiency throughput tests healthcare professionals payers toobusiness performance roche ilka gdanietz mysugr austria long impact imagine anything else type diabetes lived since nowadays wear pump constantly delivers age ten diabetes datadriven disease insulin body implanted sensor handle many numbers every day like skin sends glucose readings blood glucose levels carb intake calculate real time smartphone smartwatch right amount insulin units take list connected app mysugr goes person living diabetes stores relevant diabetes data one place make therapy decisions day even lets know detects certain pattern sucks really exhausting blood glucose readings need pay timeconsuming frustrating extra attention working mysugr since mysugr expect healthcare industry aims offer allround care people diabetes development products services open app solution specialises coaching keep us alive also make lives easier automated data tracking since mysugr hopefully give us good quality life part roche group work convinced digitalisation big role help make living diabetes less burdensome play understand pain well third coworkers also live type diabetes develop take active role raising awareness features app take account practical condition since writing one issues around lives getting views bestknown diabetes blogs germany patients board early stage goal also getting increasingly involved patient take away many therapyrelated tasks possible advocacy together colleague moderate patient diabetes patient event every year draws participants grew diabetes days blood glucose meters much bigger test took living diabetes working company focused two minutes take insulin shots eight diabetes spending free time times day addition keep handwritten diabetesrelated projects advocacy may sound logbook records mess times bit weird long impact changed diabetes care imagine anything else digital transformation happening around us pharmaceuticals division sales total sales chf billion first full year key markets ocrevus successful new product launch roches history sales pharmaceuticals division increased sales grew us international chf billion new medicines contributed region particularly china almost growth actemraroactemra rheumatoid herceptin perjeta kadcyla combined arthritis forms juvenile idiopathic arthritis herpositive breast cancer herpositive giant cell arteritis well car tcellinduced metastatic gastric cancer herceptin herceptin severe lifethreatening cytokine release syndrome sales increases mainly driven growth sales increased regions driven us us china europe japan sales affected biosimilars xolair us chronic idiopathic urticaria allergic asthma growth driven avastin advanced colorectal breast lung demand indications kidney cervical ovarian cancer relapsed glioblastoma type brain tumour sales increased lucentis us eye conditions international region us including neovascular wet agerelated macular japan declined europe degeneration macular oedema following retinal vein occlusion diabetic macular oedema diabetic mabtherarituxan forms blood retinopathy growth driven sales prefilled cancer rheumatoid arthritis certain types syringes sales increases approved vasculitis sales development impacted europe indications japan biosimilar competitionbusiness performance roche key growthdrivers chf millions herceptin oncology avastin oncology highlights medicines launched since perjeta herpositive breast cancer sales chf billion grew regions december perjeta registered countries perjeta adjuvant treatment indication strongly oncology supports continued growth also driven increased demand adjuvant ebc us neoadjuvant metastatic settings europe ocrevus ocrevus chf billion treatment neuroscience relapsing rms primary progressive ppms forms ms growth driven new patients patients requesting followup therapy alike actemraroactemra esbriet chf billion idiopathic immunology pulmonary fibrosis ipf sales continued expand driven growth us tecentriq chf million advanced xolair bladder cancer advanced lung cancer initial immunology therapy nonsquamous nsclc growth driven postlaunch uptake europe launch japan alecensa chf million alkpositive esbriet nsclc alecensa showed continued strong sales immunology growth across regions gazyvagazyvaro chf million chronic lymphocytic leukaemia cll rituximab kadcyla refractory follicular lymphoma previously oncology untreated advanced follicular lymphoma sales expanded especially europe us hemlibra chf million hemlibra approved tecentriq people haemophilia inhibitors oncology factor viii countries including us eu australia japan hemlibra also approved people haemophilia without factor viii inhibitors us countries alecensa oncology growth rates report constant exchange rates cer average rejuvenating portfolio new options patients results phase iii alex jalex studies new medicines including ocrevus perjeta alecensa added wealth evidence tecentriq alecensa hemlibra saw continued supported firstline use alecensa multiple strong uptake multiple markets patient populations within alkpositive nsclc followed rapid worldwide regulatory sales chf billion first full year approvals recently announced results third key markets ocrevus successful headtohead phase iii alesia study alecensa versus new product launch roches history addition crizotinib asian patient population alk met extremely positive responses positive advanced metastatic nsclc reinforce new markets vast majority findings alex jalex studies showing patients forms also returned followup reduction risk disease worsening death treatment twiceayear medication strong alecensa lowered risk tumour spread demand indications continued fiveyear growth brain central nervous system data showed efficacy ocrevus maintained key measures disease activity people ms treated earlier ocrevus superior alecensa approved china alk disability progression outcomes compared rms positive advanced nsclc eight months patients switched interferon betaa approval europe ppms patients switched placebo longer term safety data continue show favourable risk strong data announced tecentriq benefit profile studies triplenegative breast cancer tnbc extensivestage small cell lung cancer ocrevus approved countries people treated globally positive results announced phase iii december impassion study tecentriq plus chemotherapy nabpaclitaxel initial firstline treatment perjeta representing major advance treatment unresectable locally advanced metastatic tnbc patients breast cancer generated total sales first positive phase iii immunotherapy study chf billion launched usage continues tnbc aggressive disease limited treatment broaden study results confirm medical benefits options tecentriq chemotherapy combination additional indications including results significantly reduced risk disease worsening phase iii aphinity study adjuvant treatment death progressionfree survival pfs compared herpositive early breast cancer patients chemotherapy alone intentiontotreat high risk recurrence pdlpositive population subgroup determined phase iii openlabel extension studies opera opera ii oratorio zhou c et al primary results alesia presented esmo congress munich germany abstract lbabusiness performance roche europe us japan international eastern europe middle east africa latin america asiapacific canada form international region pdl biomarker testing showed treatment haemophilia hemlibra encouraging overall survival benefit pdl also gained us fda approval people positive population interim analysis haemophilia without factor viii inhibitors together previous approvals new medicine positive results phase iii impower indicated haemophilia patients us study tecentriq plus carboplatin etoposide along three dosing regimens subcutaneous chemotherapy initial firstline treatment treatment weekly every two weeks every four people previously untreated extensivestage weeks data studies small cell lung cancer showed tecentriq supported approval review chemotherapy helped people live significantly european medicines agency longer compared chemotherapy alone intentiontotreat population combination results kadcyla phase iii katherine study based tecentriq also significantly reduced patients herpositive early breast cancer risk disease worsening death compared ebc showed treatment kadcyla single chemotherapy alone agent led significant reduction risk disease recurrence death compared herceptin hemlibra approved people haemophilia adjuvant surgery treatment people inhibitors factor viii countries herpositive ebc residual disease present approvals transformed medical practice following neoadjuvant surgery treatment approvals expedited reviews december fda approved tecentriq first biologic therapy approved combination avastin paclitaxel carboplatin fda pemphigus vulgaris first major chemotherapy initial firstline treatment advancement treatment disease people metastatic nonsquamous nonsmall cell years lung cancer nsclc egfr alk genomic tumour aberrations additionally approvals granted fda subcutaneous formulation actemra october fda approved xofluza roactemra form juvenile idiopathic arthritis treatment influenza infection xofluza avastin form ovarian cancer firstinclass singledose oral medicine novel proposed mechanism action approved expedited review status treatment acute uncomplicated influenza people fda granted priority review status tecentriq aged years older demonstrated efficacy plus chemotherapy nabpaclitaxel initial wide range influenza viruses including firstline treatment unresectable locally advanced oseltamivirresistant strains avian strains hn metastatic tnbc people whose disease expresses hn nonclinical studies pdl protein determined pdl biomarker testing july fda granted breakthrough fda also granted approval mabthera therapy designation tecentriq combination rituxan treatment adults moderate avastin firstline treatment people severe pemphigus vulgaris rare serious life advanced metastatic hepatocellular carcinoma threatening condition characterised progressive based ongoing phase ib study imbrave painful blistering skin mucous membranes phase iii study ongoing european medicines agency ema granted prime priority medicines designation almost companys investigational medicine rg formerly known ionishttrx treatment people huntingtons disease investigational oral medicine risdiplam rg treatment divisions growth driven new products people spinal muscular atrophybusiness performance roche chf million divisional sales erivedge perjeta kadcyla gazyvagazyvaro esbriet cotellic alecensa tecentriq venclextavenclyxto ocrevus hemlibra xofluza venclextavenclyxtos sales booked partner abbvie percentage sales contribution medicines launched since increased steadily entrectinib granted expedited review lives cancer patients making optimal use status three major regulators us fda healthcare data analytics partnership breakthrough therapy designation eu ema leverage combined expertise advance prime designation japan japanese ministry use realworld evidence set new industry health labour welfare sakigake orphan standards oncology research development drug designations entrectinib development treatment ntrk fusionpositive locally late july roche completed transaction advanced metastatic solid tumours adult take ownership foundation medicine paediatric patients whose cancer progressed inc fmi us transaction accelerate following prior therapies acceptable comprehensive genomic profiling oncology standard therapies making fmis highquality comprehensive genomic profiling testing innovative data services advancing personalised healthcare commonly available together companies april roche completed acquisition leverage expertise genomics molecular flatiron health acquisition help combine information enhance development person efforts two companies committed improving alised medicines care patients cancer image touched yetbusiness performance roche gehad refky roche egypt partner life got know well ten months old doctors told went get degree pharmacy parents haemophilia never imagine biotechnology five years ago joined roche one day work would able worked different areas rheumatoid help others like personal experiences arthritis anaemia transplantation three years advantage importantly responsibility ago complete chance read article challenge person haemophilia roche developing medicine called emicizumab know well burden disease hemlibra haemophilia company much nuisance debilitating hoped could work medicine one day complications finally position product manager opened applied honestly little child even aware much haemophilia affected family work launch team emicizumab diagnosis came twisted roche egypt hope medicine ankle bleeding inside made turn shades available patients soon busy team purple green grew understood several prelaunch activities education needed careful carrying even programmes healthcare professionals spreading routine daytoday tasks always nightmare awareness haemophilia talking bleeding episodes often physicians patient groups emicizumab occurred inconvenient times parents search hospitals doctors fearful life makes easier explain burden injecting something familiar disease challenges patients face daily lives field visits school difficult times varied medical science liaisons conversation experiences toughened remember medical expert moves different level broke leg twisted ankle time come know disease skip morning lines recesses haemophilia partner life got whole month children would look strangely know well hope use thought given special privileges benefit othersscience innovation roche core business science innovation advances digital technologies datadriven analytics increasingly shape research development going forward taking personalised healthcare next level employee preparing sample roches digital pathology platform key asset programmes cancer immunotherapy data insights better informed decisions machine learning tools identify patterns morphological changes bacteria tightly linked antibiotics mode action moa providing unique fingerprint new technologies advanced analytical tools roche building wideranging expertise helping manage mine make sense large combined strengths pharmaceuticals fastgrowing datasets emerging powerful diagnostics past years made catalysts transformation healthcare company universally acknowledged pioneer terms accelerating research development rd leader first wave personalised healthcare ensuring access best possible care patients phc part efforts company developed targeted treatments starting concrete examples tremendous progress breast cancer medicine herceptin made recent years wearable devices smart phone apps continuous patient monitoring access going forward ability capture understand affordable wholegenome sequencing technology unprecedented amounts data multiple sources machine learning capabilities revealing allow higher resolution indepth hidden secrets medical images new tools view patient thus putting promise truly technologies increasingly unlock value personalised healthcare within reach physicians intent identifying best possible therapy options patients drawing unique combination strengths regulators requesting solid outcomebased data pharma diagnostic capabilities one realworld settings roof leading portfolio therapies wealthscience innovation roche material topics covered chapter product portfolio strategy rd pipeline strategy personalised healthcare expertise medicine biology world viral diversity susceptibility drugs leading companies foundation medicine hbv infections common around world flatiron global reach culture nearly million people chronically infected successful partnerships deeply committed million live china alone direct delivering meaningful sustainable value result infection hbv sizeable patients healthcare systems going forward number individuals go develop hepatocellular carcinoma one deadliest forms powered new possibilities advanced cancer analytics able create wealth new data insights opportunities across entire product vaccination highly efficacious preventing lifecycle rd value chain making infection vaccine coverage incomplete ongoing informed choices biological targets mothertochild transmission contributes pursue research innovating optimising continued propagation disease although design clinical trials ultimately improving current hbv treatments effectively suppress viral patient access right drug right time roche replication typically curative already using leveraging powerful new therefore high unmet medical need curative tools cusp next wave phc hbv therapies ultimate goal equip physicians tailormade solutions patients research shown hbv higher mutation rate previously thought surprisingly short optimising drug design closeup view viral period time virus effectively sequesters heterogeneity bacterial behaviour human cells replication machinery order historically roche pioneer proliferate billions viruses per day every powerful presence infectious disease area possible mutation represented prominent examples roche products space antivirals invirase hiv pegasys hepatitis c modern stateoftheart ultradeep sequencing tamiflu xofluza influenza antibacterials mutant viral strains quasispecies bactrim rocephin pneumonia urinary tract characterised precisely purpose roche infections etc collaborated two medical centres nether lands china obtain representative viral samples roche currently developing broad portfolio different populations parts world innovative potentially transformative medicines samples revealed variants including directacting antivirals immuno modu viral surface antigen lators treat infection hepatitis b virus hbv new antibacterials staphylococcus applying random forest modelling wellknown aureus multidrugresistant gramnegative machine learning tool data possible bacteria interlink deep genomic sequencing data information viral behaviour patient clinical project roche scientists start applying features characterisation hbv genomes sublethal concentrations number compounds used predict viral genetic features different antibiotic classes cultures clinically relevant people chronic hbv escherichia coli induces changes key bacterial infection guiding drug development efforts parameters membrane integrity cell shape individual treatment approaches dna intensity visible fluorescence microscopy exact pattern changes tightly linked machine learning antibiotic research moa providing unique fingerprint growing public health threat making frequent headlines media antimicrobial resistance machine learning perfect tool finding amr refers fact antibiotics similarities patterns large datasets meaningful increasingly losing effectiveness broad conclusions similarity morphological range common difficulttotreat bacterial changes rarely drawn merely looking images infections microorganisms acquire resistance acquired microscope however first antibacterial drugs problem widespread applying appropriate image analysis tool especially trouble gramnegative bacteria quantifying changes hundred different projected cause million deaths morphological parameters machine learning annually determine profile changes unique matches known antibiotic novel view pressing medical need new information hand roche scientists uncovered antibiotics novel modes action roche unique signatures prioritised bacterial pathways reentered space focus gram guiding drug discovery efforts thus negative bacteria like acinetobacter baumannii identification moa machine learning pseudomonas aeruginosa number provide important information support compounds preclinical development targeted antimicrobial drug development efforts aim develop antibiotics active prioritise compounds best potential diseasecausing multiresistant infections development new antibiotics crucial understand precise mode action moa genomic profiles digital biomarkers innovating compounds inhibit bacterial growth clinical trials benefit patients roche therefore applying innovative machine amount healthcare data generated around learning techniques large imagebased datasets world growing exponential rate sheer help inform drug discovery development volume medical information doubling every project required intense inhouse multidisciplinary months take example detailed investigation collaboration experts areas antibiotic cancer molecular level help research microscopybased cellular assays gene comprehensive genomic profiling continuous expression profiling informatics focus monitoring disease progression neurodegenerative statistics machine learning tools well image conditions help smartphonebased sensors analysis produce billions data points antimicrobial resistance tackling crisis health wealth nations london wellcome trust science innovation roche cupisco trial study design standard chemotherapy treatment options molecular tumour board alk ret alecensa treatment decision egfr avastin tarceva randomisation herceptin perjeta ptch smo erivedge molecular profiling braf cotellic zelboraf tissue blood responders brcaparp parpi aktpik ipatasertib cycles tmb high tecentriq chemotherapy nonresponders tmb intermlow chemo tecentriq actionable alteration molecular tumour board treatment decision primary endpoint progressionfree survival secondary endpoint overall survival cupisco study compare efficacy safety targeted therapy cancer immunotherapy guided genomic profiling versus chemotherapy patients cancer unknown primary site tools technologies generate vast median overall survival cup patients abysmally amounts data valuable nuggets lowin range one yearso information extracted also offering urgent medical need better therapies deeper insights nature diverse diseases therefore providing exciting new opportunities granular information question drug discovery development mutations driving cups urgently needed cancers caused one mutation coming terms cancer unknown primary host different genetic factors requires last two decades tremendous comprehensive genomic profiling progress comprehending treating cancer cupisco comes play understanding cancer biology molecular level led development targeted effective cupisco phase ii randomised clinical study therapies recently cancer immunotherapies recruit histologically confirmed cup based improved knowledge tumour patients countries eventually totalling immunology shown impressive clinical results participants number approved roche cancer hand cancer unknown primary medicines studied trial study site cup still devastating diagnosis compare efficacy safety targeted therapy approved treatments available cancer immunotherapy versus chemotherapy cancer diagnoses fall category means primary endpoint progressionfree survival although tumour metastases detected ground breaking study represents shift away possible find originating tumour treating cancer based organ origin foundation medicine genomic profiling report along clinical findings convert specific treatment decision unprecedented clinical trial setting potential pave way truly targeted personalised treatment strategy understanding individual patient journey multiple sclerosis living multiple sclerosis ms makes unpredictable uncertain existence treatments advanced need understand disease order improve outcomes patients despite advances imaging ability measure roche conducting research programme created people ms better understand disease changed much decades individual disease course usually based visits clinic take place twice year providing limited snapshot means although populationlevel understanding ms good knowledge treating based clinically relevant genomic individual patient journey ms alterations driving cancer growth end roche collaborating foundation medicine world roche created floodlight research programme leading molecular insights company matching design smartphonebased tests patients unique genomic profile known therapies potential monitor disease daily basis clinical trials parameter measures coordination mobility information processing speed addition performing thorough molecular mood neurologist pocket programme workup every patient virtual molecular also includes floodlight open roches first open tumour boards bringing together oncologists access study anyone enrol data radiologists surgeons pathologists health point person contributes unique care professionals set cupisco open dataset designed help move ms research study discuss results patients individual forwardscience innovation roche detecting progression disease earlier nmp clinical ngs reporting software quantifiable manner significant innovation solution richly curated uptodate ms community addition furthering knowledge base genetic variants designed help understanding ms improving individual labs accurately efficiently interpret clinical patient care hope could accelerate drug significance mutations identify therapy development improve ability bring new options clinical trials match designed drugs market faster efficiently labs want ngs testing inhouse need robust clinical reporting solution expanding identifying clinically actionable variants already available navify portfolio clinical clinical labs looking offer nextgeneration decision support software eg navify tumor board sequencing ngs cancer testing often challenged nmp simplify analysis complex complexities analysis reporting ngs data aiding labs identifying reporting difficulty encounter accurately assessing clinically actionable somatic mutations clinical significance genomic variants inform sophisticated software integral part optimal clinical treatment options based best navify decision support portfolio suite practices realworld evidence cloudbased workflow solutions apps streamline clinical workflows integrate patient data differentiating benign pathogenic variants multiple sources help access relevant small feat classifying degree knowledge support treatment decisions actionability pathogenic variants underpinning clinical decisions terms appropriateness partnering success cancer treatment options even challenging growing complexity healthcare coupled requires review multitude public sources explosion data multiple often siloed guidelines properly interpret clinical sources means future medicine built significance decide course action partnerships single stakeholder able go alone shape view roche developed clinical decision require new ways partnering collaborating support solution called navify mutation profiler nmp go beyond traditional boundaries internally planned launch early enable externally roche also expanding diagnostic labs overcome one great challenges collaborative efforts increasingly combining clinical ngs workflow namely translating rich resources unique tools complex datasets actionable treatment options technologies partners combining vivo vitro diagnostics created software integrates otherwise early roche ge healthcare announced fragmented clinical molecular genomic real entering longterm strategic alliance world data treatment plans health outcomes develop industryfirst digital platform software combining platform roches wide solutions marrying vivo vitro diagnostic ranging oncology expertise collaboration set insights would allow seamless integration push phc new level many cancer analysis part comprehensive clinical decision patients healthcare providers support solution navify tumor board roche syapse collaboration comprises four key global strategic partnership offer physicians objectives develop precision medicine insights comprehensive data dashboard pulls together product generate realworld evidence support information imaging ct mri scans accelerated access innovative therapies well blood tests tissue samples gene sequencing plus syapses clinical applications create evidence latest clinical trials precision medicine programme enable health economics outcomes research build patient alliance help accelerate delivery data reported outcomes programme understand driven phc care teams patients healthcare precision medicines effect healthrelated quality industry apply advanced analytics vivo life accelerate enrolment clinical trials data ge healthcares medical imaging matching eligible patients trials partnership monitoring equipment together vitro data syapse complementary ongoing roches biomarker tissue pathology sequencing efforts flatiron health companies address portfolio goal jointly develop comarket distinct healthcare systems providers clinical decision support software faster networks accurate decisionm aking clinicians enabling earlier diagnosis individualised treatment patients syapses network comprises one million cancer patients nearly hospitals us south collaborating phc progress cancer korea covers newly diagnosed cancer january roche entered collaboration patients us strong network adds agreement san franciscobased syapse key roches efforts bring novel therapies patients player healthcare formed syapse faster including accelerating regulatory filingsscience innovation roche harnessing frontline scientific technologies gene therapy offers hope patients choroideraemia rare disease eye lead complete blindness two roche research organisationspred roche betting gene therapy rare eye disease pharma research early development gred choroideraemia rare monogenic recessive retinal genentech research early developmentare disease caused mutations specific gene affecting pioneering new ways tackling challenging disease males progressive peripheral conditions high unmet medical need vision loss night blindness usually first show patients teen years culminate common activities relentless effort complete blindness later life first understand underlying disease biology molecular level identify relevant gene therapy could hold key alleviating biomarkers help find right patients condition gene therapy therapeutic genes targeted treatment right time ultimate goal specific segments dna introduced target develop compounds zero intended cells order replace missing faulty genes biological target perfectly druglike properties example mutant chm gene fail properly well tolerated highly effective encode fully functional proteins number highlights many gene therapy traditionally faced real challenge innovative rd programmes areas namely finding effective gene delivery vehicles ophthalmology oncology immunology vectors fulfil intended purpose satisfactorily however highly optimised thirdgeneration adeno opening new avenues cancer immunotherapy associated virus aav vectors perfected roche investing ever developing great vehicles gene transfer locate innovative treatment options help persons enter specific cells high degree precision immune system fight cancer building approved cancer immunotherapy cit tecentriq us company molecular therapeutics development programme takes comprehensive dmt forefront aav technology approach pursuing goal restoring cancer choroideraemia may lend particularly well immunity pioneering modality announcing expanded longterm partnership dmt profound understanding underlying april roche entered new terrain science cit extensive experience engineering choroideraemia project first foray gene new sophisticated modalities unique therapy position drive forward development new potentially firstinclass cancer immunotherapies key advantage aav invented dmt benefit patients treat choroideraemia mode application namely intravitreal injection intravitreal application stimulating immunity targeted way avoids risk retinal detachment checkpoint inhibitors cpis tecentriq involve surgery case traditional able remove brake inhibitory pathway subretinal application furthermore immune system resume attack modality possible reach whole retina tumour cells contrast mode action injecting functional working chm gene investigational medicine fapilv works eye aav ability penetrate stimulating immune system fapilv may either vitreous space access entire retinal target tissue work synergistically cpis show efficacy including photoreceptors majority patients respond stopped responding genetic retinal diseases occur high hopes aav gene therapy fapilv homegrown roche molecule made could prove great value people affected two parts one part highaffinity antibody choroideraemia roche preparing directed fibroblast activation protein fap investigational new drug ind submission found wide variety cancer cells fda order soon start first human trial solid tumours blood cancers space second part ilv engineered form ilscience innovation roche increase due diligence awareness men affected choroideraemia symptoms usually first show patients teen years cytokine protein involved activation cells preventing one surface proteins immune system upon intravenous infusion called tigit binding pvr specific receptor monoclonal antibody portion recognises binds tumour cells fap thereby concentrating ilv fapexpressing tumour tissue ilv portion stimulates immune within tumours cells impaired ability response activates natural killer cells attack cancer cells due expression inhibitory cytotoxic cells fighting cancer receptors surface exhausted tigit expressed surface exhausted cells roche scientists engineered ilv way similar pd hampering tigits interaction retains powerful immunestimulating properties receptor pvr goal help remove il simultaneously displaying reduced additional brake exhausted cells thus activity cells dampen antitumour immune reactivating attack tumour responses also designed longer tiragolumab novel checkpoint inhibitor providing halflife superior riskbenefit profile compared added activity top tecentriq especially normal il binding fap leads inflamed tumours high pdltigit expression buildup fapilv concentration tumour tissue application immune modulator allow specifically tigit regulates another activating longer activation higher concentrations fap receptor surface cells cd tigit expressing tumours expressed surface cell limit activation cell disrupting cd function fapilv investigated four phase iib scientists therefore created antibody could phase ii studies number cancer types block tigit binding pvr way freeing renal cell cancer nonsmall cell lung cancer alone cd bind pvr instead consequently turn combination therapies eg tecentriq green light therefore blocking tigit removes brake also allows activating removing brake turning green light molecule signal tiragolumab good novel cancer immunotherapy agent monoclonal safety profile single agent also combined antibody tiragolumab developed record speed tecentriq patients currently enrolled genentech scientists research clinic randomised phase ii nons mall cell lung cancer helping revive tumourfighting ability proofofconcept study researchers pioneering cuttingedge technologies address challenging diseases high unmet medical need advancing medicines people immune circulating autoantibodies produced b cells diseases inflammatory cytokine proteins generated recent advances understanding immune myeloid cells chronic spontaneous urticaria pathways guide research activities inflammatory csu highly debilitating skin disease auto autoimmune diseases insights help yield immunity also known play role almost new targets new treatments new ways thinking patients vital capabilities addressing diseases high unmet medical need diseases current standards care antitumour necrosis factors ra immuno blocking drivers autoimmune disease sup pressants sle antihistamines csu fail rheumatoid arthritis ra systemic lupus achieve sustained remission relieve symptoms erythematosus sle occur immune majority patients therefore systems begin attacking organs tissues significant unmet need novel therapeutics conditions characterised increase improved efficacy lower toxicityscience innovation roche brutons tyrosine kinase btk protein fibrotic disease process ultimately leads identified key activator b cells cirrhosis liver failure immune cell types myeloid cells btk plays important role development proliferation silent liver disease symptoms immune cell types btk blockade likely develop people metabolic may represent opportunity treatment disorders type diabetes dyslipidaemia broad range autoimmune diseases ra sle obesity currently approved therapies csu condition obvious need effective treatment scientists genentech faced daunting task designing btk inhibitor right combination could done improve situation potency specificity stability took several fibroblast growth factor fgf member years hard work achieve feat finally metabolic fgf family expressed primarily researchers found investigational small molecule liver regulates fat metabolism potent offered targeted approach modulating b cells mobiliser fat liver finding way target myeloid cells intended manner pathway highly specific manner could hold key treatment space molecules name fenebrutinib currently clinical trials highly potent based insight genentech scientists created selective orally administered reversible non antibody molecule mimicking fgf signalling covalent inhibitor btk based attributes hypothesis compound could expected acceptable safety profile remove socalled insult fat accumulation phase ii study ra recently met primary nash liver halt reverse inflammatory endpoint superior efficacy placebo data fibrotic process restore healthy liver function disclosed conference lupus based deep understanding fgf receptor csu phase ii studies ongoing expected biology scientists designed bispecific antibody completed act fgf hormone mimetic since receptor hormone combination heterodimer targeting hormone halt liver damage two different proteins fgfrc klb bispecific nonalcoholic steatohepatitis nash fibrotic antibody targeting seemed ideally suited liver disease driven accumulation excess generating longacting safe drug fat liver triggers inflammatory desired receptor selectivity antifgfr antibodies developed cancer injuries intestinal system digestive therapies act inhibiting fgfr pathway thus tract resulting chronic inflammation pattern preventing unwanted cell replication fgfrklb mucosal ulcerations surface intestinal signalling via fgf proliferative mediates wall injuries elicit hyperinflammatory beneficial metabolic signals specifically response immune system standard treatments activates fgfrklb pathway without activating consisted immunosuppressive drugs fgfr alone addition targets metabolic antitnfs drugs combat disease symptoms signalling tissues express heterodimer blocking immune response reduces adipose tissue molecule completing inflammation multipled ose phase ib study obese patients nonalcoholic fatty liver disease precursor nash genentech scientists come alternative idea based dual functionality il instead unique potential harness fgf biology suppressing immune system order alleviate reducing liver fat deposition fgfrklb symptoms aim get root cause ibd bispecific antibody also beneficial effects promoting regenerative protective functions parameters insulin triglycerides il epithelial tissue thereby potentially cholesterol therefore able provide healing disease could achieved longterm metabolic health benefits new medicine would represent firstinclass disease modifying truly transformative therapy ibd first nonimmunosuppressive therapy patients inflammatory bowel diseases cytokine interleukin il important fact il long history company component immune system plays key cytokine cell receptor discovered role wound injury occurs fact il genentech scientists early dual mechanism action setting established biology behind il first helps restore repair epithelial cell wall scientists engineered new modality recombinant lines skin internal organs fusion protein ilfc links carefully modified colon second helps fight bacteria parts il unique dual mechanism enter site injury causing infection action customised fusion protein would latter promoting production first nonimmunosuppressive therapy disease antimicrobial peptides area designed block il signal apply phase ii clinical study inflammatory bowel diseases ibd crohns getting started investigating safety efficacy disease ulcerative colitis uc associated ilfc ibdscience innovation roche pharmaceuticals clinical pipeline breakthrough therapy designations six years phase phase li phase ill registration oncology inflammation immunology neuroscience infectious diseases ophthalmology others pipeline new molecular entities covers broad range diseases highly innovative technologies applied create produce active molecules importance intellectual property innovation continued innovation key providing new improved therapies crucial patients well longterm commercial success patents intellectual property rights provide time limited exclusivity innovations thus enabling substantial investment research development disclosure inventions patents fosters development new improved therapies image touched yetscience innovation roche michael negrin israel three years later telling story according doctors supposed identified could receive targeted therapy talking gave year live specific mutation developed aggressive bladder cancer three years later telling storyalmost results surprising doctor cancerfree living life mutation caused bladder cancer actually typical breast cancer patients often years olda husband father grandfather joke became first bladder cancer patient three years ago noticed blood urine israel treated medicines breast cancer went doctor asked series patientsa combination two targeted therapies tests diagnosed bladder cancer treatment condition improved markedly team doctors hospital decided within months undergo surgery bladder removed plan changed operation test specific diagnosis surgeons realised cancer spread could made could offered detected earlier decided specific therapy doctor explained remove bladder instead put substantial differences tumours even chemotherapy located site body therefore quite sure test great benefit chemotherapy five days week every several patients believe added alternating week challenge hooked different healthcare systems packages tubes process usually lasted costs covered underwent chemotherapy hours day chemotherapy went months damaging also five months seemed change improve condition way prognosis told doctors busy ready die oncologist told three years important another test wanted leading normal active life new undergo comprehensive genomic test called granddaughter well additional time foundationone explained test might valuable many others around help identify specific mutation worldaccess healthcare roche tackling challenges access healthcare mission ensure roche working together healthcare systems delivers rapid broad sustainable patient access novel products people waiting hallway kenyatta national hospital nairobi kenyaone largest medical institutions east africa stepping globally hospital pharmacy abidjan cte divoire hospital many cancer treatments take place thanks agreement roche signed cte divoire ministry health facilitate improved access innovative treatments hepatitis b c breast cancer roche passionate following new department develop holistic access science areas high unmet medical need bring strategies roche works healthcare systems transformative medicines diagnostic tests deliver rapid broad sustainable patient access patients also realise products innovative medicines diagnostics want benefit patients actually reach bring products many patients need access important topic us fast possible sustainably healthcare systems roche almost half world lacks access essential health services million people still pushed know alone extreme poverty health expenses important roche engage stakeholders continuing efforts try change different healthcare systems worldwide roche global scale therefore developed systematic comprehensive approach working affiliates around world september roche launched integrated efforts made identify barriers global access department preparation preventing patients benefiting working internal external products steps need taken order stakeholders define roche access mission facilitate better access based analysis access strategy capabilities required develop partnerships tailored solutions country appropriate organisations needed deliver bycountry many situations theaccess healthcare roche material topics covered chapter sustainable healthcare pricing disease awareness treatment education growth strategy emerging markets product think also meaning million people complete range offerings patient support benefit treatment diagnosed programmes awareness campaigns disease respective disease monitoring access medicine foundation recognised part efforts follow patient journey strong accesstomedicine strategy area disease awareness diagnosis treatment general access medicine management roche funding make sure people aware ranked access medicine index disease educate support index analyses worlds largest researchbased people receiving proper early diagnosis pharmaceutical companies make prevent disease worsening patients products accessible low middleincome diagnosed adequate healthcare capacity countries place order deliver right treatments capabilities run infusion facilities industry collaborations join forces sufficient numbers trained nurses doctors roche plays leading role access accelerated difficult find countries also initiative launched crossindustry address treatments funded patients collaboration aims reduce barriers prevention protected excessive financial burden treatment care noncommunicable diseases ncds low middleincome countries address access barriers strategy end pharmaceutical companies focuses four imperatives access associations involved programme affordability value recognition capacity outcome partners world bank group certainty following strategy already union international cancer control uicc able amplify access patients participate low middleincome countries two important cancer medicines herceptin initiative founding member uiccs mabtherarituxan included city cancer challenge ccan support model list essential medicines effective sustainable cancer care delivery models represents increase population access selected cities four key learning cities kicked close million challenge asuncin paraguay cali colombia kumasi ghana yangon myanmar last year expanded focus also include participation provides insights perjeta new standard care combination international community local civil society herceptin women herpositive breast public private sectors best work together cancer goal accelerate patient access first four cities participating institutions increase number patients treated healthcare professionals patients herceptin plus perjeta emerging markets connected transform approach local factor six cancer care solutions world health organization world bank group tracking universal health coverage global monitoring report part roches commitment increasing access patient platform p launched sustainable cancer care announced address challenges digital solution october would act lead industry puts patients centre enables affiliates partner working cities develop region develop innovative efficient programmes pilot model engagement ccan improve experience patients healthcare could scaled globally leading efforts professionals hcps alike support cities across globe spearhead design planning implementation stateofthe platform consists four categoriespatient art solutions cancer care far kigali rwanda onboarding treatment monitoring scheme porto alegre brazil tbilisi georgia management adverse event capturealong chosen cities next phase ccan patient hcp portal solution allows patients take control disease management using digital platforms support patients improve wellbeing experience asiapacific region ambition ensure provide sense community connecting patients access roches innovative patients hcps treatments patient support programmes psps fundamental component access strategies p also work towards reducing duplication region help us realise goal across psp processes drive better insights analytics support launch processes products date different psps afford opportunity make use realworld asiapacific serving patients data ensure compliance local laws projects shown roche number malaysia first country launch p hurdles region needed resolved thailand taiwan followed later year instance common approach psps singapore australia due follow asiapacific programmes always linked longterm access strategies platform making health data accessible available support better management analysis health data potential help fight diseases programmes ensure faster patient access medicines drive future healthcareif accessible health systems around world collect different kinds data genomic data realworld data clinical trial data etc many sources yet infrastructure used capture data often integrated leaving data disconnected incomplete patients asiapacific supported psps unstructuredaccess healthcare roche data drives healthcare healthcare data access research healthcare information practice cphin leverage quality health data drive prescribing access research decisions across canada connecting data important mission discussions early collaborations health delivering personalised healthcare canadian canada department canadian government personalized healthcare innovation network responsible national public health cphin initiative example started order positive several partnerships confirmed build platform makes health data findable biopharmaceutical technology data accessible established collaboration management companies recruitment roche canada canadian cancer trials partners ongoing group canadas genomics enterprise university health network university waterloo platform funded cphin partners initiative run notforprofit organisation leverage funding opportunities federal provincial governments network cphin integrated data platform provides designing revenue model ensure search engine access realtime data streams cphin integrated data platform financially maintaining patient privacy realtime selfsustaining long term access access data insights platform foster agreements granted users within canadian informed decisions every facet healthcare international private sector public sector turn accelerate innovation improve including researchers hospitals institutions payers efficiency lower costs speed approval processes governments clinicians able access improve patient care data data platform free charge continuing fight hiv aids diagnosis improved countries great progress made last years highest disease burden collaboration tackling hiv pandemic number clinton health access initiative partners people dying every year aidsrelated illnesses provide accessible affordable pricing worldwide decreased steadily peak reagents consumables needed hiv testing million less million train healthcare workers roche also offers support early diagnosis appropriate treatment programmes help build healthcare system monitoring possible people living capacity including participation publicprivate hiv normal healthy lifespans partnerships ppps instance centers disease control prevention us yet areas hit hardest hiv vast also invest developing countries helping region subsaharan africa access healthcare equip laboratories newest technologies centres diagnose treat follow hiv patient care extremely limited worldwide every august formally launched partnership fourth person living hiv still know kenya medical research institute status installing cobas hiv assays global access program partnership aims leading provider hiv viral load testing ensure people kenya access roche created global access program expand hivaids testing viral load monitoring access quality sustainable diagnostic testing ppp kenya initiatives like roche scientific contributing unaids goal campus south africa demonstrate ongoing aim people living commitment africa capacity building hiv know disease status skills development go beyond supply diagnosed hiv infection receive instruments sustainable pricing sustained antiretroviral therapy receiving antiretroviral therapy number hiv tests run viral suppression four times higher programme launched idea expand global since start global access program access program areas potentially access hiv viral load tests early infant include additional disease areas wwwunaidsorgenresourcesfactsheetaccess healthcare roche small amount blood persons fingertip needed cobas plasma separation card simplifies blood collection sample transportation even remote areas redefining reach reliable testing quantitative testing patients hiv living roche continues invest innovative products remote areaseven places experience solutions expand access launched temperatures c humidity sample cobas plasma separation card stable easy protected journey lab days touse sample collection device hiv plasma viral even extreme conditions load testing size credit card fundamentally changes way samples taken processed samples sent post viral load hiv testing tests carried uptodate results care personalised adjusted soon necessary traditionally viral load results required blood followup monitoring people hivpositive samples cooled transport lab achieved viral suppression helps small amount blood fingertip stay healthy cobas plasma separation card allows reliableaccess healthcare roche merula steagall abrasta abrale brazil focus getting proper understanding patient needs lived thalassaemia age two sharing business best practices among ngos almost years years living today group ngos countries severe blood disorder working disease others cancer however really impactful unite realised value networks working private public efforts led working groups influence decisionmakers bring colleagues set movement together change cancer brings together institutions private public spheres april contacted mother two work collaborative agenda aim boys thalassaemia know asked implement improve nationallevel policies could help find information cancer prevention control disorder told addition spurred impact already able set first interest area patient advocacy observatory analyse monitor government brazilian thalassaemia society abrasta microdata cancer online education platform going curtail activities poor funding health professionals physicians lack interest among parents offered established developed several research president take new steps revive began projects patient centre focus work ministry health two years getting proper understanding patient needs able transform treatment situation listening patient primary brazil working experts helped objective improve outcomes changing treatment outcomes provide better access adequate treatment formed abrale brazilian society patient groups need work blood cancers widen impact political industry bring patient perspective decisionmakers many physicians designing clinical trials early could help worked also treating blood cancers shorten process focus important expanded formation things patients care quality life red alianza latina network patient organisations survival want aggressive interventions across latin america would help us upscaling understandour people roche roche care people caring people roche helps ensure patients get better diagnoses therapies year young people begin vocational training roche basel kaiseraugst switzerland gathering insights future working lives people purpose work together design structures processes principles governing operate encourage employees share insights improvements needed throughout history roche dedicated dedicated ensuring roche remains delivering driving innovation helps place creative gifted passionate people manage health breakthrough people desire work peoplethe collective medicines diagnostic solutions unwavering source innovationare critical commitment stems unique highly factor success adaptable culture brings together core beliefs purpose people values enables us keeping touch keeping proactively evolve dramatically shifting changing business needs landscape roche people understand power collaboration internally externally todays world interconnected digitalised working effectively across different geographies increasingly complex new reality requires time zones multiple projects priorities ever innovation flexibility speed also staying aligned critical global demands ability challenge paradigms business recognised helping quickly recognise thoughtfully respond employees managers stay connected challenges opportunities roche dynamic fastpaced environment requires transforming way work make sure different type dialogue cadence consistently meet needs patients introduced checkins part customers future new people practicesour people roche material topics chapter employee engagement talent retention compensationbenefits leadership commitments organisational effectiveness checkins conversations manager step uncovering ideas determining best employee focus employee solutions aim consistentdeveloping ideally happening facetoface conversations testing new better faster ways working scheduled impromptu address ultimately help patients range important topics including contributions personal growth professional development pharmaceuticals division provides good initiated either employee example comprising global regional local manager checkins used commercial structures setup needed undergo discuss daytoday business focus individual substantial change efficient effective employees discussion tailored agile design sprints introduced identify needs checkins launched across address key challenges purposebuilt teams organisation change employees managers assembled different departments levels communicate already form essential organisation featured willingness part people roche work together embrace ambiguity challenge status quo increasing agility drive manage change offering workplace sees potential everyone changes business political environments roche welcome value visible require us look individuals invisible differences among people age work together different ways also gender sexual orientation culture thinking styles become agile organisation roche believe diversity inclusion essential defined agility ideal balance speed generating innovationa culmination wide stability flexibility speed enables us seize range opinions perspectives create great opportunities arise analysis potentially transformative ideas realworld data example flexibility helps us adjust approaches suit new situations launched grouplevel campaign titled stability provides clear important foundation personal campaign showed via personal employees strategic framework stories submitted employees high level leadership commitments code conduct commitment supporting diverse inclusive commitment sustainability examples work environment focus individual also emphasised dedication ensuring roche work together design structures work environment offers people needboth processes principles governing operate office different areas personal encourage employees share insights lives needs include different ways working improvements needed transparency flexible schedules unpaid leave options challenges opportunities critical first needing care sick relative diversity inclusion di part overall mainly caused number structural changes corporate goals one fiveyear corporate goals organisation impacting various key positions increase number women key positions well increasing number key position rocheability network example incumbents experience developing diverse inclusive workplace shaped established regions achieved fiveyear group engaged colleagues support goal gender diversity key position sponsor initiative fosters inclusion people incumbents diverse experience made good disabilities teams based basel kaiser progress first three years however augst also supporting employees saw actual decrease compared caregivers partners family members global wellbeing week challenged participants reflect digital behaviourour people roche fiveyear goals increase representation women key leadership roles increase representation people established developing region experience key leadership roles top quartile ranking overall employee engagement score measured global employee opinion survey goal baseline disabilities bottomup effort rewarded connecting learning prestigious roche pharma next award roche believe expertise people located various functions affiliates often best basis people living working longer ever decisions opposed topdown approach multiple generations working side side innovation flourishes diverse people connect offering opportunities benefit others collaborate essentially creating networks perspectives reverse mentoring become widely utilised opportunity leverage peoples strengths purposebuilt networks platform utilised support learning participating colleagues gained crossfunctional projects good example valuable insights wide range areas networks supported roche platform popular apps simplify activities sharing provides suggestions start networkbased work experiences connections project set meaningful way leverage existing expertise company striking right balance productively across functions project striving achieve balance something groups formed around particular business need common yet personal finding follow principle identifying keeping balance todays environment suitable team address need projects running challenge global live well initiative principle serve example starting roche promotes culture health wellbeing point faster development products employees address physical mental developing company view particular policy needs people onsite exercise facilities regulatory topic experts different areas healthscreening programmes medical counselling services even legal financial advice resources workday new human resources system launched offerings differ every affiliate depending offers additional resource creating local needs opportunities internal networks enables employees showcase professional expertise experiences aspirations global wellbeing week focused specifically roche community availability digital wellbeing week sites information empowers recruiters project teams introduced interested employees latest trends individuals search specific expertise find topics digital social wellbeing event right individual quickly easily end showcased new tools challenged participants eight months launch employees reflect digital behaviour started fill individual professional profiles significant impact physical mental health workday make visible wellbeing interesting opportunities working roche offers variety opportunities time must agile selfaware grow develop impactful development authentic must understand changes activities typically go beyond traditional classroom environment around believe leader ship training necessarily directly linked approach much effective empowering taking new role many regions functions offer people helping grow develop changing perspectives programme enables contribute employees experience different area role period three six months programme order accelerate transformation senior employees opportunity work projects leaders organisation participated develop leadership skills gain insights new kinesis programme introduced may career path might suitable kinesis aims help leaders understand future programmes help people think mindset behaviours directly impact career development decide effectiveness leadership programme want take technical role starts challenging leaders confront patterns scientist software engineer perhaps become thought successful past may people manager senior leader limit effectiveness introduced principles practices agile organisations roche believe everybody potential participants explore organisational transformation grow learn people levels encouraged learn requirements leader learn accomplishments challenges engage others transformation journey every day insights learnings help boost entire organisations ability move forward nurturing attracting talent time learnings provide opportunities growth development opportunity grow improve utilise critical attracting retaining people good entire roche community valuable source leadership science technology core information experience business providing right development opportunities scientific technical talent leadership journey vital one example scientific technical great leadership essential attracting talent workstream engages multiple retaining people talent dedication departments across several functions focus leadership commitments introduced remain specific theme interaction important foundation leadership culture functions human resources departments fosters understanding people need evolving environment continually grow thrive including ways fully leverage presents new challenges opportunities recognise scientific contributions expectations placed leaders fundamentally changed past decade today leaders need digitalisation already deeply embedded demonstrate new capabilities embrace leader roche codelife initiative effort raise ship style mindset focused people roches profile among digital talent may notour people roche technologies challenges c personalised healthcare c lab automation java haematology python diagnostics mongodb cancer immunotherapy html drug discovery docker clincal trials spring outcome prediction asw oncology r safety report processing jupyter notebook javascript sql linux nodejs tibico angularjs jenkins user interactions technical talents codelife initiative covering technologies challenges codelife initiative aims showcase technology driving innovation healthcare example highlighted technologies help solve challenges diagnosis yet aware extent digitalisation countries switzerland germany codelife changing world diagnosis treatment roche sites basel kaiseraugst codeliferochecom options patients codelife competition example teaching methodology open university teams individuals either content meet highest standards apprentices external roche process gain valuable experience professions including participants could learn significant impact informatics biology chemistry automation healthcare could digital capabilities electronics areas closely coupled translate directly benefits people research manufacturing programming need urgently codelife initiative printing robotics also part pro interactions online campaigns gramme provide insights development driven visits views manufacturing medicines apprentices also website recognising coding capabilities participate exchanges sites could also exist unconventional places within mannheim penzberg germany company launched initiatives identify digital talents across organisation talented people across world collectively engage solving challenging problems believe valuesintegrity courage passion purposedoing patients need next progress digitalisation roche also together making meaningful difference reflected vocational training offered day helping ensure roche continues apprenticeship system well established innovate benefit patientsour people roche jutta steinseifer roche switzerland need better understand patients consider benefit two years ago went doctor patient patient realise routine mammography screening offered important involve patients women germany received partners even drug development information diagnosis gift prior need better understand patients consider christmas house full guests since benefit acceptable terms journey looking breast cancer toxicity treatment going receive side rebel life whole new mindset approach physicians become one course always need involved treatment worked medical director expertise advise patients regarding herceptin breast cancer medicine treatment options need develop helped millions women around world filled products focus patient needs learned hope also provided scientific personal cancer journey doctors arguments needed challenge status quo always know really matters patients need involve patients directly must one thing learned journey seat table difficult discussions doctors much easier bring along second pair ears attached addition working external patient functioning brain brain often overwhelmed groups tap knowledge information two years later back work within roche many colleagues also thanks also support wife daughter patients live patients work friends within roche sometimes helped need next one way real advice sometimes achieving roche patient networks huge asset group joined return treatmentpatientsareus word advice make use mammography screening made available city town roche already right track making always take family member friend great efforts put patients centre work afraid ask questions get second however even better example opinion satisfied first oncology still room improvement recommendation make trials patientfriendlierenvironment roche minimising impact environment roche protecting environment legal social obligation integral operations sustainability top priority construction projects like site kaiseraugst switzerland proactively seeking new technologies regularly inspect pharmaceutical diagnostics manufacturing facilities environmental performance implementation environmental policy environmental protection central long goods environment roches reputation term priority everchanging world roche corporate audit team inspects pharma protecting environment integral part ceutical diagnostics manufacturing facilities operations taken seriously throughout environmental performance implementation life cycle products corporate principles environmental policy keeping legal safety security health environmental requirements internal standards also make protection policy ensure commit recommendations future improvements highest standards environmental protection made committed continuously invested chf million environmental monitoring key performance indicators eg five infrastructure chf million environmental year goals aim cover operating costs including services personnel least key performance indicator environmental management compliance believe education awareness training roches environmental risks mitigated via best ways foster employee engagement multid isciplinary system prevention responsibility mind successful environmental management system ems conduct regular training sessions regional proactive system reduces costs increases conferences workshops provide online environment efficiencies enhances competitiveness dedicated tools local languages employees rochecom team employees around globe identify potential employees participated approximately environment risks could possibly cause damage people hours dedicated trainingenvironment roche material topics chapter environmental responsibility noise pollution emissions water primary energy emissions air roche ecobalance landfilled waste water consumption minimising environmental footprint fiveyear goals measure total environmental impact using ecobalance metric system ecobalance points allocated ecologically relevant parameters million pointsemployee metric provides us global view impacting earths ecosystems allows local site management freedom develop energy consumption locally appropriate strategies objectives gj ffeemployee reducing environmental impact points added related total number employees enables us monitor general waste environmental impact per employee strategic kgemployee goal reduce ecobalance th e n wn ed h v e b w eee n r ae ia mch ine gd tt oh rs e dgo ua cl e u r f pi rn ince water consumption year improvements terms memployee decreasing energy consumption air emissions water consumption weight chemical goal waste led improvement compared ffe fossil fuel equivalent weighted water stress changes related respectively developed swiss federal office environment compliant latest guidelines decreasing energy consumption energy management programme twofold success reducing energy consumption first seek improve energy efficiency carbon dioxide emissions credited global operations turn reduces initiatives like renovation chimney environmental impact well strain basel site resulted significant increase energy supply chain costs secondly energy efficiency approximately endeavour reduce usage fossil fuels cut energy result avoidance consumption increase proportion sustainable tonnes co per year monetary terms energy set energysaving action plans means roche save approximately sites include implementation chf per year fuel costs innovative technologies continuous upgrading infrastructure improve energy efficiency reduced emissions due hybrid cars since roche diagnostics indianapolis total energy consumption decreased converted car fleet hybrid sales grew energy used buildings cars new strategy helped reduce stationary equipment gas fuel oil waste electricity amount energy used fleet vehicles district heating comparable used approximately less energy compared energy used due business air travel decreased terms carbon dioxide emissions approximately still contributes moving hybrid cars reduced emissions fifth roches total energy consumption approximately energy consumption terajoules share sustainable energy total scope scope energy energy scope rochecom consumption gj environment employee resourcesand scope goal rawmaterials business flights sustainable nonsustainable scope energy generated within facilities eg combustion gas scope purchased energy data collected group gj gigajouleenvironment roche energy use selected types energy used due business air travel video teleconferencing facilities established sites widely used employees encouraged use trains consolidate several business trips one grid electricity first priority reduce usage energy energy use look ways improving efficiencies heat recovery addition encourage use renewable energy wherever makes sense natural gas energy used company vehicles stipulate company car fleets consist vehicles use less mjkm sustainable construction san francisco campus wellness building occupants genentech genentech long incorporating sustainability achieved leed platinum certification principles planning development another new building campus completed south san francisco ssf campus adopted building represents several firsts holistic approach encompasses green building genentech including net zeroenergy performance design well employee health wellbeing annual energy generated buildings since genentech reduced greenhouse gas solar photovoltaic system solar hot water panels emissions energy used ssf campus equivalent amount energy used thanks part green building programme building every year additionally lifecycle assessment already achieved leed gold certification completed project design demonstrated campus community center genentech pursuing environmental benefits buildings wood well building certification firstofitskind construction including saving embodied standard emphasises health productivity carbon compared steel structure reducing greenhouse gas emissions greenhouse gas ghg emissionssuch emissions air roche sites carbon dioxideresulting human activities low levels considered responsible accelerating global warming climate change industry one source emissions air tonnes emissions must take appropriate measures reduce impact international agreements paris agreement roche actively supports vocs well national legislation define targets particulates schedules reducing emissions working nitrogen oxides towards goalset reduce sulphur dioxide scope ghg emissions per employee volatile organic compounds ten years emissions strategy prescribes continuous another initiative reduce ghg emissions roche improvement manufacturing sites reduce use halogenated refrigerants aim avoid reduce control air pollutants used cooling equipment remain line ecobalance goals despite increased atmosphere long period time production resulting continued growth therefore committed reduction use objective keep emissions air halogens compared penzberg low levels achieved past years germany working local suppliers develop new technologies using natural refrigerants able reduce scope ghg emissions date able replace kg implementing energysaving measures halogenated substances thus avoiding tons reduced amount fuel use heat cool carbon dioxide equivalents approach applying operate sites ghg emissions originating environmentally friendly refrigeration honoured transformation purchased energy consumed regional government us scope also reduced halogenated hydrocarbons tonnes emissions since total projects rochecom completed resulting avoidance approximately environment tonnes co emissions led inventory emissionstoair estimated costsaving approximately consumed released andtowater chf million global inventory including chugai genentech ventanaenvironment roche tonnes co emissions avoided since long term goal fully substitute fossil nuclear energies energy renewable sources diagnostics site suzhou china installed photovoltaic panels cover almost energy needs administration building co equivalent emissions tonnes scope fuel combustion halogenated hydrocarbons scope marketbased locationbased total scope marketbased scope business flights energyintensive utilities waste due changes reporting methodology number different reported compressed air liquid nitrogen reducing water consumption waste currently roche highusage operations efficiency meets ecology areas water scarcity waterrelated risks aim implement following waste manage nevertheless adapt conservation reduction ment strategy waste activities avoid reduce programmes according local conditions needs reuse recycle thermally destroy permit californian sites example use drought landfilling last resort even resistant landscaping sites collect inert materials slag ashes waste recycle water cooling towers creating minimisation reduction measures closedloop system reduces water use reducing restricted production processes evaluated total water consumption important part implemented across operations roche overall environmental target water goal strive ecoefficient solutions show reflects reduction environmental burden economic benefit eg reduction raw material water usage discharge disposal cost landfilled incinerated waste tonnes water withdrawn million water consumed general waste million generated water discharged chemical waste treatment plant generated million contaminated soil organic matter construction waste discharged waterways prior data collected separately treatment heavy metals discharged roche innovation center copenhagen waterways denmark presses sells waste recycling treatment kg companies monetary compensation enough toenvironment roche tonnes co emissions avoided next years reagent production transportation cover waste press recycling waste avoids address customer demands greener products carbon dioxide emissions linked incineration supply chains public concerns chemicals procedures kg cardboard pharmaceuticals environment kg paper pressed sold avoid approximately kg carbon dioxide pharmaceuticals environment initiative therefore benefits environment traces pharmaceutical products enter company environment variety ways including via manufacturing process improper disposal unused developing new diagnostic system reducing medicines natural metabolic processes impact environment crucial element following normal patient use roche acting process innovative instrument design concerns impact pharmaceuticals vast experience test development allow us environment considering entire life cycle operate lower reagent volumes therefore products mabtherarituxan herceptin produce smaller reagent carriers generate less avastin perjeta lucentis monoclonal waste per test implementation cobas e antibodies generated chf billion pack green cobas c pack green avoid sales belong defined class active tonnes co emission next pharmaceutical ingredients apis exempt ten years reagent production transportation european medicines evaluation agency guideline represents flights basel san environmental risk assessment francisco ecological mindset helps customers low excretion rate deemed present product address key challenges lab testing significant risk sewage works surface waters stewardship sustainability efforts reflect commitment therefore termed benign nature rochecom product stewardship roche aim minimise constitute environmentally sustainable compounds environment safety security health environmental impacts pharmaceutical products however product products devices efforts also help subject rigorous environmental risk assessment stewardshipcommunity engagement roche striving longterm community engagement working together bring change better take variety forms mobilise resources serve catalysts strengthen sustain local communities funds raised annual roche childrens walk go initiatives supporting education health social development around world nine roche ambassadors chance visit selam childrens villages ethiopia experience firsthand progress made resources put good use paths strong societies mother living roche childrens centre mumbai learns embroidery skillbased workshops conducted centre help parents acquire new skills generate increased income families strengthening communities one reason employees worldwide operate part roches responsibility global join forces annual roche childrens citizen philanthropic engagement directed walk raise money local projects toward supporting humanitarian social projects employees countries participated fostering science education art culture effort matching contribution made well providing longterm disaster relief support roche chf million collected projects run international ngos year support childrens projects headquarters well local projects managed affiliates collaboration local ngos providing holistic care children cancer know needs countries best one project funded childrens walk partnership st jude india childcare making meaningful difference takes time centres organisation provides shelter happens partnerships given time care children undergoing cancer therapy opportunity evolve approach countries like india providing access medicine honoured achieving excellent score often takes effort making medicines corporate citizenship philanthropy available commercially also need dow jones sustainability indices recognition create environment patients able important crucial projects thrive start complete treatment resources put good usecommunity engagement roche material topics chapter community engagement sustainable healthcare disease awareness treatment education although therapy paediatric cancer subsidised travels across state maharashtra teach basic sometimes even free charge tata occupational skills parents st jude india centres memorial hospital mumbai dropout rate state significant simple reason two thirds patients come outside mumbai connecting local healthcare systems housing city beyond means partnership st jude india well roof heads weakened disease way another roche alliance made history effects chemotherapy children prone already beginning journey years ago infection find difficult fight cancer healthcare train phelophepa one successful humanitarian projects south africa roche opened centre mumbai roche health clinic pharmacy clinic campus st jude india offers clean safe place board delivers primary healthcare health stay children cancer given time education impoverished communities remote families feel home areas phelophepa trains run weeks year duration treatment get nutritional support travel remote communities annually education counselling apart roches inception first phelophepa train took financial contribution employees volunteer time place years ago today two trains running passion arrange recreational activities like provided treatment six million patients performing dance storytelling sessions dispensed prescriptions partnership helped decrease overall dropout rate treatment paediatric cancer mumbai since children found temporary home away home since overall dropout rate treatment roche centre completed treatment paediatric cancer mumbai decreased watching project flourish expanded partnership st jude india opening second centre eastern region assam roche also established mobile training van unlocking potentials growing talents education break vicious cycle poverty foundation renovation work better teaching children skills knowledge needed employment conditions local workers develop improve lives therefore roches philanthropic engagement often accompanied addition promoting school readiness educational component programme launched unicef ethiopia among initiatives supported roche carefully choose local partners ensure recognised ethiopian ministry share values integrity fairness accountability education childtochild project improve transparency nine employees school readiness peer tutoring older among top childrens walk fundraisers children help roche children opportunity visit one partnersthe selam accessed early learning opportunities childrens villages ethiopia witnessed initiative progress made funds around corner around world also foster education closer home selam nonprofit organisation provides numerous projects designed promote interest housing holistic care orphan children science technology among young people ethiopia develop become self since roche founding sponsor reliant selams quality schools run ages international swiss talent forum think tank technical vocational training centres young adults world address also benefit disadvantaged children youths global longterm challenges time surrounding communities connecting students experts decisionmakers lateral thinkers international swiss talent roche supports total children forum creates space innovation interaction live five orphan homes run house mothers debate develop new solutions globally addis ababa city yeka sub city kotebe wereda significant issues young adults aged bole sub city fifty youths vocational training years countries world selams schools training centres objective came together find novel answers challenges allow students focus entirely faced future urban life education removing financial pressure could cities handle fastgrowing populations otherwise hinder progress students cities become selfsufficient next year completed training far able students chance reflect artificial find job quickly additional funding helps intelligencecommunity engagement roche due diligence legal framework high school students involved fouryear coursework futurelab school year futurelab genentech initiative developed genentech provide monthly support benefits accrue cooperation south san francisco unified sides volunteers say programmes school district designed inspire k students like science garage make likely stay kindergarten th grade explorations genentech report developed skills careers science technology engineering result volunteering mathematics stem sharing skills experiences science garage newest part futurelab part roches ongoing commitment offers fouryear biotech pathway designed give improve education developing countries high school students chance discover exciting microsecondments combine knowhow field biotechnology science garage starts skills roche employees local ngos build threeweek biotech unit ninth graders capacity deliver sustainable outputs increase compulsory biology course impact umbrella collaboration school year students ran experiment field b education partnerships facilitates classical genetics gene identification knowledgesharing europe africa three roche employees served guest lecturers appetite biotechnology namibia university science demonstrated many students technology nust windhoek roche partner continued pathway take additional elective university two ran programme biotech coursework course two years environmental health science supporting students become familiar variety coaching students handson exercises concepts laboratory techniques career pathways taught logistics supply chain management biotech industry year students students assignments south san francisco school district conducted close colla boration university involved fouryear programme integrating real business cases curriculum encouraging employability supporting durable apart teachers delivering units knowledge transfer courses employee volunteers fromintegrity business roche continued commitment integrity business applying high ethical standards activities foundation success integrity pays stakeholders society large also business overall work closely suppliers construction engineering ensure sustainability business matter culture aim translate formal guidelines businessintegrated compliance creates positive impact business practice expectations clear patients healthcare shedding light grey areas professionals authorities society large part comprehensive compliance management trust act ethically responsibly efforts facilitate businessintegrated impact bound law reputational oriented decisions simplifying processes reasons live values adhering principle trust verify mean employees left working integrity professional virtue asked count supportive connected employees everyone expected assess risks compliance officer network unethical behaviour within area accountability prevent mitigate adopt face organisation role models corrective measures roche philosophy serves employees general managers gms play central approach starting point culture integrity role fostering ethical behaviour respective rochecom embedded everyday business results teams mind compliance induction approach compliant behaviour programme new gms launched recentintegrity business roche material topics covered chapter compliance occupational accidents drug efficacy safety counterfeiting data transparency clinical trials patient organisation support supply chain management years tailored affiliates needs used help colleagues tool developed discuss compliance topics help practical provide approval workflow repository examples overall objective make sure documents compliantly manage interactions gm able foster culture every employee healthcare professionals hcps tool assists accountable right thing carrying diagnostics affiliate panama interactions responsibilities hcps central america caribbean countries concept evaluated another example embed compliance diagnostics diabetes care affiliates business compliance maturity questionnaire also stemming creative idea pharma originally developed france tool helps ceuticals organisation compliance app compliance officer top management understand available pharmaceuticals diagnostics compliance status identify areas advancement diabetes care teams throughout latin america discuss compliance different click button sales staff retrieve information business teams wider organisation compliance key compliance criteria requirements business partners different departments judged app also used tool analysing reference different topics planning compliance programmes campaigns example speakup culture communication management case noncompliance adapted affiliates questionnaire serves valuable tool local compliance management identify compliance risks set priorities accordingly compliance employees used roche group speakup line pioneering integration digital tools available languages countries chief way simplifying access relevant information compliance officer received reports relating alleged compliance continuously enhance violations code conduct via business ethics integration digital tools instance latin incident reporting system unfounded america challenges highly heterogeneous founded still investigation region terms legislation country size result employment contracts agreements market characteristics met innovative business partners terminated grounds unethical solutions assist medical decisions services behaviour ensuring operational resilience keeping ongoing efforts sustainable consequently track achieving development roche striving continuous midterm targets period improvement areas safety health security years implemented health wellbeing employees roche variety initiatives improve already excellent business partner organisations always track record areas accidents health top priority consequently business partners expected meet rigorous standards result number accidents constant policy bearing fruit since establishment low see graph vast majority slips new diagnostics site suzhou china trips household accident rate workers spent seven million working hours low single accident resulting longer absence reportable accidents lead fluctuations accident rate key figure set feasible ambitious goals responsible prescient handling chemicals established health safety committees roche june roche complied mandatory production sites many sites according requirement european unions regulation risk levels registration evaluation authorisation restriction chemicals reach registering employee health safety existing substances volume one tonne per year regarding chemicals roche traditionally gone beyond legal requirements instance initiated pilot project european chemicals agency echa partner companies share archived data scientific community improve knowledge toxicity chemical substances thus help reduce number animal studies another initiative involves substances high concern svhc listed goal echa set ambitious goal losttime illness rate roche accident rate voluntarily phasing svhc losttime accident rate number workrelated accidents products processes worldwide within ten years working days lost per year due accidents appearing list technically feasible threeyear averageintegrity business roche protecting harm tampering digitalisation become integral approach security digital solutions applied area product travel security example travel tracker system facilitates ontrip support rapid identification travellers case emergency enables roche security team contact colleagues travelling inbuilt email sms handled emergency events supported people worldwide counterfeit pharmaceuticals may devoid active ingredients may contain harmful substances state incorrect dosages inappropriately packaged labelled masquerading medicines put employ several anticounterfeit strategies combat counterfeiting help ensure patients risk treatment failure dangerous quality products side effects todays global trade system opens possibilities introducing counterfeit products regular supply chain coordinate counter efforts collaborate international criminal efforts combined greater awareness anticounterfeiting investigations authorities stricter legislation help ensure rochecomanti safe supply critical medicines patients need counterfeiting roche genentech chugai members pharmaceutical security institute hosts database product crime cases comparison data provides opportunity business continuity management identify specific logistics companies distributors september hurricane maria left trail death notified law enforcement destruction puerto rico island home one roches authorities roche closed suspected three manufacturing sites glucose test strips area cases confirmed diabetes care storm impacted employees local affiliate well roche site hit power outage damage also use internal analytical skills examine overall infrastructure one substantial challenge aftermath samples counterfeiting besides identifying storm connectivity especially access roche composition medicine impurities network employees worked hard keep impact contamination scientists analyse ink packaging disruption minimum preventing shortages products leaflets blisters paper investigate counter diabetes patients worldwide possible processes feits detected different locations around world place focused improving resilience network find originated source today puerto rico affiliate back full operations partnerships lasting future view improving sustainable patients stakeholders rwd partnerships patients roche updated directive roche accesses uses rwd undertakings collaborating patient groups patients activities aim ensure data protection guidelines acknowledge role played allowing use data drive medical innovation increasingly empowered vocal patient population directive patients defined sustainability supply human rights broadly include patient organisations patient united nations guiding principles business groups patient associ ations patient advocacy groups human rights embedded operations patient communities patient experts online patient multiple means assessing risks communities family members caregivers potential violations promoting awareness fostering individual patients due diligence strengthening legal framework collaborating collective actions transparent interacting patients able gain communication greater understanding need patients perspective guide us clinical development conducted human rights risk assessment example defining meaningful clinical trial endpoints crossfunctional representatives also reflected newly launched patient supported corporate sustainability committee platform forpatients provides disease education identified human rights potentially well information roche clinical trials susceptible violations well associated layperson language provides relevant risks enhance awareness created video information makes easier caregivers explained human rights roches endeavours patients connect possible clinical trial sites simple message employees within sphere influence ensure human rights respected respect privacy data protection patients believe access use realworld data carried riskassessments approximately rochecom rwd legitimate purposes benefits patients business critical suppliers broadened patientorganisations provided appropriate safeguards place supplier due diligence also expanded interactions patients stake collaboration businesscritical suppliers forpatients holders need respect privacy year systematically identify riskassess critical tier forpatientsrochecom adjusted policy framework data privacy light suppliers specifically looked countries new european union general data protection industries known high risks violation position rwd regulation gdpr took opportunity human rights total found high rochecomrwd evaluate current practices developed roadmap risk tier suppliers among logistics ensure requirements gdpr met companies nigeria thailand temporary human rights addition involvement many stakeholders labour companies mexico verified rochecomapproach roche elaborated position paper access tier suppliers mitigation plans place humanrights use rwd explains tremendous value suppliersintegrity business roche human rights approach benchmark increase awareness enhance legal framework transparent communication assess risks foster due diligence collaborate collective actions also continued supplier sustainability baselbased brgerspital provides assurance visits support external audit important services roche introducing firms completed visits area inclusive internship programme local organisation labour conditions findings also wants improve diversity workforce include excessive overtime improper pay internship open people varying overtime insufficient number rest days disabilities ranging physical disabilities inadequate payment social benefits worked neurodevelopmental conditions suppliers address findings example sustainability assurance visit chinese supplier pharmaceutical manufacturing equipment revealed unsatisfactory standards working conditions especially regards health engaging public policy stakeholders public policy safety environment workers convinced responsible constructive form rochecom excessive overtime received insufficient lobbying interest parties involved society approach training addition company carry whole seek inform work closely government publicpolicy regular fire drills supplier since successfully officials order highlight address issues affect implemented corrective actions healthcare industry advance regulatory framework updated good practice guidelines working focus abilities government officials appropriate roche discloses recognition human rights ensures contributions signs transparency register public people right treated dignity authorities switzerland spent chf million rocheability network instance fosters includes payments industry associations various inclusion basel kaiseraugst employees chambers commerce financial assistance trade unions disabilities focuses strengths abilities donations political parties cantonal federal level individual basel kaiseraugst site donations political parties low doubledigit started work inclusive providers thousand range swiss francs together accounted plans expand collaborations one example approximately total contributions donations safety security health environment image touched yetintegrity business roche dr nicole gusset sma switzerland red line patient organisations never cross daughter victoria diagnosed spinal granted helps us understand muscular atrophy sma year birth inputs relevant transparent communication caregiver child sma need sharing confidential information patient everythingtime space money energy emotions organisations needed order us make sma affects aspects life merciless meaningful contribution red line killer constantly tries grab child patient organisations never cross interest trying stay ahead keep patients wellbeing reach centre decisions actions compromises soon devastating diagnosis started efforts contribute development healthcare industry undergoing change therapeutics make sure would meet increasing digitalisation access data patients needs needed knowledge partners better informed demanding patients battle founded patient organisation sma enough safeguards protect individual switzerland joined forces sma europe aware potential consequences make family gives great support victoria informed decisions like think personal data constant motivator driving force helps belong individual also see incredible raise patients voice pursue inclusion opportunity lies ahead applying big data discussions decisionmaking drug surely fusion discoveries big human development data technological advancements fundamentally change face medicine sma switzerland works closely stakeholders drug development process patient input star treklike scenario patients scanned essential levels cooperation medical tricorder identify health status pharmaceutical companies currently provide rescanned treatment may longer expertise working groups advisory boards science fiction personally sma nearer protocol design trial operations communications future foresee combination different therapies tailored patients personal needs paired partnership work well goals graceful robotic devices replace clumsy clearly formulated insight internal processes wheelchairs mechanical aids todaycorporate governance roche corporate governance principles put focus business activities sustainable value creation innovation prescribe management culture conforming recognised standards good corporate governance policy transparent communication roche continously modernising infrastructure ensure successful sustainable operations principles roches corporate governance principles put focus roche complies relevant business activities sustainable value creation corporate governance requirements particular innovation prescribe management culture applicable laws swiss stock exchange conforming recognised standards good corporate six swiss exchange directives swiss code governance policy transparent communication best practice corporate governance promulgated principles build basis successful swiss business federation economiesuisse implementation roches commitment serving companys internal governance framework stakeholders particularly articles incorporation bylaws embodies principles needed ensure strong board directors represents companys businesses managed supervised interests shareholders stakeholders manner consistent good corporate governance highly skilled managers act integrity including necessary checks balances extremely important printed annual report contains selected links th consecutive year roche roche website wwwrochecom readers recognised sustainable company thus provided snapshot pharmaceuticals index dow jones sustainability company reporting date also directed indices djsi based indepth analysis sources consult time economic social environmental performance uptodate information corporate governance djsi serve benchmark investors integrate roche whereas annual report covers single sustainability considerations portfolios financial year ending december website sustainability core business practices contains information permanent nature award reflects commitment running well latest roche news companys articles business way ethical responsible incorporation bylaws curricula vitae creates longterm value stakeholders current former members board directors corporate executive committee published corporate governance report sets website structures processes rules roche takes basis wellfunctioning corporate governance details please refer following report annual general meeting annual general meeting board directors board directors board committees board committees presidium nomination committee remuneration committee audit committee corporate governance sustainability committee corporate executive corporate executive committee committee ceo ceo ceo cfo hr general roche group pharmaceuticals diagnostics counsel enlarged corporate enlarged corporate executive committee executive committee gred pred partnering communications rochecomgovernancecorporate governance roche board directors th annual general meeting agm addition agm elected dr christoph franz roche holding ltd march shareholders andr hoffmann prof dr richard p lifton reelected dr christoph franz chairman bernard poussot peter r voser members board directors remuneration committee furthermore agm reelected andr hoffmann organising meeting immediately following prof sir john bell julie brown paul bulcke anita agm board directors determined hauser prof dr richard p lifton dr andreas oeri structure composition remaining bernard poussot dr severin schwan dr claudia committees shown see also pages suessmuth dyckerhoff peter r voser term board directors corporate one year provided articles incorporation executive committee board directors board directors board committees board committees presidium nomination committee remuneration committee audit committee corporate governance sustainability committee composition name year birth first elected board directors dr christoph franz c e chairman andr hoffmann representative c e vicechairman shareholder group pooled voting rights dr andreas oeri representative e shareholder group pooled voting rights prof sir john bell b e julie brown b e paul bulcke b e anita hauser e prof dr richard p lifton c e bernard poussot c e dr severin schwan f dr claudia suessmuth dyckerhoff b e peter r voser c e secretary dr gottlieb keller board directors honorary chairman dr fritz gerber board directors corporate governance sustainability committee b audit committee c remuneration committee presidiumnomination committee e nonexecutive director f executive director committee chairperson march forthcoming agm july roche announced dr andreas board directors nominates chairman oeri informed board directors remaining members board directors stand reelection member reelection board directors annual general meeting conclude year term office addition board directors proposes prof dr jrg duschmal fifthgeneration descendant dr hans clevers professor molecular genetics founder roche confirmed interest university medical center utrecht netherlands standing election member board election board directors directors agm previous year board directors moreover board directors nominates nominates bdo ag independent proxy dr christoph franz andr hoffmann prof dr period conclusion richard p lifton bernard poussot peter r voser ordinary annual general meeting shareholders reelection members remuneration election agm committee agm corporate executive committee daniel oday ceo roche pharmaceuticals roland diggelmann ceo roche diagnostics member corporate executive committee member corporate executive committee left stepped role december roche pursue career outside company end february prior assuming effective september successor new responsibilities outside roche provide named dr michael heuer former head regions support ensure smooth transition activities europe middle east africa latin america roche diagnostics assumed ad interim william bill anderson former ceo genentech leadership roches diagnostics division appointed ceo roche pharmaceuticals effective become member corporate executive january new member corporate committee executive committee reporting dr severin schwan ceo roche group corporate executive corporate executive committee committee ceo ceo ceo cfo hr general roche group pharmaceuticals diagnostics counsel enlarged corporate enlarged corporate executive committee executive committee gred pred partnering communicationscorporate governance roche composition name year birth position since corporate executive dr severin schwan ceo roche group committee daniel oday ceo roche pharmaceuticals dr michael heuer ceo roche diagnostics dr alan hippe chief financial officer cristina wilbur head group human resources dr gottlieb keller general counsel enlarged corporate dr michael varney head genentech research executive committee early development gred dr william pao head roche pharma research early development pred dr james h sabry global head pharma partnering dr stephan feldhaus head group communications secretary corporate perolof attinger executive committee statutory auditors kpmg klynveld peat marwick goerdeler sa reporting years roche holding ltd kpmg ag since auditor charge john morris ian starkey mark baillache business year chief compliance officer dr urs jaisli prof john c reed head roche pharma research head genentech partnering appointed early development pred left roche personal global head pharma partnering new reasons april order return united member enlarged corporate executive states effective april william pao former committee new role combines genentech global head oncology discovery pharma partnering functions furthermore translational area pred appointed osamu nagayama retired enlarged successor member enlarged corporate executive committee joined corporate executive committee effective july dr sophie kornowskibonnet information member corporate head roche partnering member enlarged executive committee enlarged corporate corporate executive committee left company executive committee listed see also pages pursue career outside roche effective board directors corporate august dr james h sabry former global executive committee group structure shareholders roches operating businesses organised integrated roche pharmaceuticals diagnostics two divisions pharmaceuticals diagnostics division consists following four business areas pharmaceuticals division comprises two business centralised point care solutions molecular segments roche pharmaceuticals chugai whereas diagnostics tissue diagnostics diabetes care genentech former third segment pharmaceuticals roche pharmaceuticals incl genentech chugai centralised point care solutions diagnostics molecular diagnostics tissue diagnostics composition diabetes care dr andreas oeri chairman corporate governance sustainability committee andr hoffmann chairman remuneration committeecorporate governance roche business activities carried group andr hoffmann vicechairman board six exchange subsidiaries associated companies detailed directors chairman remuneration regulation information roche holding ltd significant committee dr andreas oeri member sixexchange subsidiaries associated companies including board directors chairman boards regulationcom company name listing information domicile share corporate governance sustainability committee enhome capital equity interest listed finance report serve respective capacities board publications note roche group consolidated financial committees representatives shareholder significant statements list subsidiaries associates group pooled voting rights receive shareholders remuneration set forth remuneration report major shareholders listed finance report finance report note notes roche group consolidated roche group consolidated financial statements financial statements equity attributable roche related parties exception shareholders related parties pages dr jrg duschmal worked postdoc note financial statements roche roche end september holding ltd significant shareholders relationships exist shareholders pooled addition significant shareholders published voting rights relevant webpage disclosure office six exchange regulation crossshareholdings capital structure information roches capital structure provided protecting interests nes holders described finance report notes financial statements articles incorporation roche holding ltd roche holding ltd additional details contained articles incorporation roche information debt instruments holding ltd issued outstanding bonds provided finance report note roche group movement recognised amounts last three consolidated financial statements debt financial years detailed finance report notes financial statements roche holding ltd information employee stock options provided finance report note roche group consolidated financial statements equity company share capital chf compensation plans including detailed divided fully paid bearer shares information stocksettled stock appreciation nominal value chf restrictions rights ssars plan restricted stock units exercise voting rights shares upon rsus plan performance share plan psp deposit shares voted without restrictions roche connect roche option plan authorised conditional capital roche issued options apart employee stock options described finance report note addition nonvoting equity securities roche group consolidated financial statements nes issued bearer form form equity compensation plans options part share capital confer voting rights issued connection debt instruments nes confers rights one share participate available earnings liquidation proceeds neither options awarded employees debt following repayment share capital roches nes instruments issued effect rights pertaining thereto including provisions roches share capital rochecomarticleofincorporation board directors corporate executive committee information member board period lack existing business directors member corporate connections group subsidiary independent executive committee listed pages roches board directors independence definition members board directors age limit based definition swiss code best restriction term office curricula vitae practice corporate governance economiesuisse current former members last five complemented specific preceding criteria years bodies information see rochecomboardofdirectors including information years first election additional positions memberships principles governance principles activities available continuously updated delegation competence reservation powers internet management group companies executive bodies company include economic rules pursuant article para point vegv environmental social topics principles number permitted activities board together internal organisation directors corporate executive committee board directors division authority members outlined articles responsibilities board management incorporation roche holding ltd remits board committees information control mechanisms available since annual general meeting elected board dealings corporate management members board directors chairman governed bylaws board directors members remuneration committee annual basis board directors roche holding ltd elections nominee voted separately organised ensure group conducts see articles incorporation roche businesses responsibly focus holding ltd minutes th annual longterm value creation end roche board general meeting roche holding ltd held delegated certain responsibilities several march committees composition chairpersons december described exception dr severin schwan none committees authorities responsibilities members board directors office defined detail bylaws board end member roches corporate directors executive committee served executive capacity group subsidiary five committees chaired independent financial years preceeding current reporting directors rochecomboardofdirectors rochecomexecutivecommittee rochecomarticleofincorporation rochecomannualgeneralmeetings rochecomarticleofincorporation rochecomcommittees rochecomarticleofincorporationcorporate governance roche board directors board committees board directors presidium nomination committee board committees remuneration committee audit committee corporate governance sustainability committee corporate executive corporate executive committee committee according bylaws board directors pharmaceuticals diagnostics divisions board meeting may convened without chairman global functions conduct formal risk assessment present request members roche process least year must develop risk plans board meets year assess chairmans material risks monitored performance meeting attended deviations reviewed regular performance dialogues chairman chaired vicechairman consolidated group risk report including target risk profile discussed corporate executive part management information system committee approved together group mis board directors regularly informed business plan material risks reviewed important issues sales performance board yearly basis effectiveness risk etc board access electronic information management process monitored group risk platform provides timely information advisory team overall process regularly board directors boards committees reviewed external auditors findings presented system controls set forth audit committee full board details risk management including risk factors board directors established system risk management policy see risk management controls continuously monitored website financial risk management specifically audit committee corporate governance described finance report sustainability committee board system internal controls financial reporting directors consists following elements see pages finance report report operating financial risks risk internal audit management system group audit reports general counsel roche group established risk management direct access gives regular briefings audit process covering entire company system committee corporate governance place identify manage types risks sustainability committee ongoing activities potentially affecting business including economic audit reports chief audit risk advisory environmental social impacts risks executive attends audit committee partly opportunities containing stakeholder input corporate governance sustainability committee board directors highest governance meetings external auditors group audit body involved roches risk management policy sets independent appraisal function evaluates approach accompanying responsibilities reviews groups activities service rochecomriskmanagement additional information provided finance report note roche group consolidated financial statements risk management management annual audit plan yearly trading company stock following blackout defined focus areas eg market access thirdparty periods effect management validated senior management december january presented audit committee roche april april group committed maintaining high standard june july internal control throughout worldwide october october operations management responsible assessing business risks aspects operation blackout periods changed chairman implementing effective efficient processes board directors circumstances warrant controls whilst ensuring compliance internal external rules regulations board directors met meetings conducting operational audits group audit generally hours length including determines managements response risks fullday meeting addition day visit surrounding business processes systems major subsidiary evaluates appropriateness completeness efficiency processes controls action plans board committees met follows implement necessary changes enhancements presidium board directorsnomination developed together businessauditee committee meetings approx hours tracked completion remuneration committee meetings approx statutory auditors see hours chief compliance officer compliance officers audit committee meetings approx hours subsidiaries see safety health environmental protection corporate governance sustainability department committee meetings approx hours corporate sustainability committee science ethics advisory group seag board directors regularly conducts issues relating genetics genetic engineering assessment selfassessmentassessment third parties via electronical survey personal members corporate executive committee interviews performance third invited attend meetings board directors party evaluation conducted report person agenda items concerning situation warrants members corporate executive committee members enlarged corporate executive maximum ordinary notice period twelve committee may also invited attend board months changeofcontrol clauses committees invite chairman board employment contracts corporate executive committee members deliver reports committee meetings may elect management contracts fall commission independent expert reports call within scope subsection annex services consultants six directive information relating corporate governance year several blackout periods imposed senior employees prohibited rochecomenvironment rochecomsustainability rochecomethicalconflicts remuneration committee members recuse deliberations decisions matters affect interests figures indicate actual length meetings include directors extensive premeeting preparations postmeeting followup activitiescorporate governance roche dr andreas oeri chairman corporate governance sustainability committee attendance board board committee meetings corporate presidium governance nomination remuneration audit sustainability board committee committee committee committee number meetings ch franz hoffmann j bell j brown p bulcke hauser rp lifton oeri b poussot schwan c suessmuth dyckerhoff p r voser member committee remuneration shareholdings loans rules aol details regarding remuneration shareholdings loans content method determining content board cec compensation shareholding programmes rules principles basic principles elements compensation applicable performance shareholding programmes serving former related pay members board directors corporate rules principles executive committee together description allocation equity securities authorities procedure determining convertible rights options set forth separate remuneration report additional amount payments pages finance report notes members executive roche group consolidated financial committee appointed statements equity attributable roche shareholders vote pay general related parties pages listed meeting shareholders note financial statements roche holding rules loans credit facilities ltd board executive shareholdings postemployment benefits rules vote pay following rules remuneration shareholdings agm loans board directors board corporate executive committee cec set forth articles incorporation aoi participatory rights shareholders participatory rights shareholders defined articles incorporation roches articles incorporation roche shareholders representing shares nominal value shares issued bearer restrictions least chf million request placement admission annual general meetings items agenda annual general meeting exception shares must deposited within must done later days specified period date meeting date meeting admittance card must issued shareholders name provided articles rules issue instructions incorporation shareholder elect independent proxy rules electronic represented third party annual general participation agm laid meeting corresponding invitation agm regulated articles incorporation articles incorporation contain restrictions exercise voting rights quorum requirements stipulated conformity swiss code obligations rochecomarticleofincorporationcorporate governance roche change control defensive measures articles incorporation contain provisions would terminated event acquisition mandatory bid rule swiss law applies vesting period restrictions preexisting awards would removed options could changeofcontrol clauses exercised immediately components remuneration based roche nes relationship statutory auditors annual general meeting roche holding ltd march shareholders voted appoint millions chf kpmg ag kpmg statutory auditors auditing services auditrelated services based existing legal requirements swiss assurance code obligations article concerning nonstatutory audits maximum term office seven years auditor tax services charge ian starkey auditorincharge since services business year replaced mark baillache total starting business year information long auditors auditorincharge statutory auditors elected year serving capacities provided annual general meeting statutory auditors participate audit committee meetings prepare written oral reports auditing services provided legally required results audits audit committee oversees assesses auditors makes recommendations auditrelated services include assurance board information authorities accounting services provided auditors responsibilities audit committee see article necessarily provided statutory auditor bylaws statutory auditors participated services go beyond legal requirements meetings audit committee could include attestation services comfort letters consents consultations reports statutory auditor consolidated financial statements financial statements tax services include services respect found pages respectively compliance tax returns tax advice except finance report services related audit tax kpmg received following remuneration services include advice relating process services statutory auditors roche holding ltd improvements regulations trainings auditors roche companies including chugai rochecomarticleofincorporation company formal policy governing limits agreed audit committee engagement statutory auditor nonaudit potential nonaudit service engagement reviewed services policy prohibits certain services policy authority proceed provided permits certain services given relationship independent proxy recent years bdo ag served independent rules issue instructions proxy annual general meeting independent proxy rules electronic march shareholders elected bdo ag participation agm laid independent proxy period corresponding invitation agm conclusion ordinary annual general regulated articles incorporation meeting shareholders bdo ag paid services annual general meeting according expenditure totalling chf chf information policy provided articles incorporation relevant information documents including corporate notices published swiss official media releases investor updates presentations gazette commerce daily newspapers analyst investor conferences available designated board directors basler zeitung internet publications available finanz und wirtschaft lagefi le temps neue rochecompublications ordered zrcher zeitung email baselwarehouseservicesrochecom fax roche reports halfyear fullyear results business reports published print andor online contact address investor relations formats media events addition detailed f hoffmannla roche ltd investor relations firstquarter nine months sales figures group finance basel switzerland published year april october tel current list publication dates available fax english german internet additional information including details specific contact persons available internet rochecomarticleofincorporation rochecommedia rochecominvestors rochecominvestorscontactscorporate governance roche chief compliance officer compliance officers network chief compliance officer compliance addition roche established business ethics officers network committed ensuring incident reporting beir system enables roche group code conduct consistently chief compliance officer capture track complied throughout roche group also monitor alleged violations initial reports serves contact person shareholders employees local compliance officers resolution customers suppliers general public issues relating implementation compliance business ethics incidents recorded system code employees parties become group internal investigation department aware violations roche group code conduct regionallocal management receives specific bring attention managers concrete information alleged violation supervisors local compliance officer report roche group code conduct one certain chief compliance officer dr urs jaisli predefined categories corporate governance direct phone number email sustainability committee audit ursjaislirochecom disclosures treated committee board directors informed confidentially addition end substantial violations managements corrective employees may anonymously report irregularities actions made complaints mother tongue via speakup line starting december new compliance chief compliance officer reports general tool group level socalled roche group code counsel also submits regular reports conduct help advice line introduced corporate governance sustainability committee strives provide guidance case questions needed audit committee board uncertainties interpretation roche directors group code conduct reference documents furthermore serve platform ideas suggestions concerning documents nonapplicabilitynegative disclosure expressly noted information contained provided six swiss exchange corporate mentioned herein either nonapplicable governance directive commentary thereto omission construed negative declaration rochecomcodeofconduct rochecomriskmanagementremuneration report roche material topics covered chapter executive remuneration remuneration report shows commitment fair performancebased resultsoriented compensation policy links employees interests various stakeholder groups modern attractive conditions key aspects roches interaction employees partners society general principles roches success depends substantially global company like roche marketcompetitive expertise motivation performance remuneration plays key role along performance employees conviction forms basis based transparent compensation structure ensure compensation policy compensation packages competitive structure individual components regularly roche aims remunerate employees fairly benchmarked swiss european international transparently line market conditions criteria remuneration guidelines enable participate appropriately underlying principles also subject regular companys success pursue goal providing outside comparisons competitive performancebased resultsoriented compensation however compensation policy one factor safeguarding roches future success another key strive balanced mix fixed variable element corporate culture offers employees compensation components geared employees conditions make best possible position management responsibility contribution shared corporate goal improving healthcare patients includes sound value compensation firstly variable components intended create system based integrity courage passion policy additional financial incentives achieve corporate time decentralised management rochecom goals keep innovation consistently high approach plays major role wide scope rewards level increasing value company individual decisionmaking respectful interactions creates stakeholder groups secondly order openness diversity wideranging training sound value allow employees managers participate development opportunities attractive working system companys business success adequate compensation environment unidimensional diminishment rochecom measures key objectives incentivised questions remuneration would fall far short livingour annual bonus payments longterm securities values based programmes roche committed fair performancebased resultsoriented compensation policy links employees interests various stakeholder groupsremuneration report roche remuneration decision process approval framework overview terms longterm oriented performance year remuneration committee roches share plan psp awards decided annually board directors decides remuneration board board directors acting upon recommendations members members groups corporate remuneration committee see executive committee remuneration decision process approval framework beneficiary remuneration board directors bod corporate executive decision approval components chairman c committee cec incl ceo roche group base payremuneration bonus c remuneration committee stocksettled stock appreciation rights annual general performance share plan board directors upon meeting recommendation remuneration committee decisions pension c remuneration committee remuneration committee tracks market data since total aggregate amounts based salaries leading global pharmaceutical decisions submitted general companies major swiss companies reports meeting approval implementing ordinance findings full board external consulting excessive compensation listed corporations firm pricewaterhousecoopers pwc assists verordnung gegen bermssige vergtungen bei remuneration committee roche performing brsenkotierten aktiengesellschaften vegv market comparisons advising information general meeting shall vote annually binding remuneration committees remit powers effect approval remuneration procedures making remuneration decisions board directors resolved board found bylaws roche board directors directors corporate executive committee articles incorporation also details see outlined sections principles governing specific remuneration components see peer set abbott laboratories abbvie amgen astellas astrazeneca bayer bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck co novartis pfizer sanofi takeda change composition peer set compared abb credit suisse lafargeholcim nestl sonova straumann swiss ubs zurich insurance rochecomarticleofincorporation rochecomarticleofincorporation andr hoffmann chairman remuneration committee peer set abbott laboratories abbvie amgen astellas astrazeneca abb bayer credit suisse roche bristolmyers squibb lafargeholcim eli lilly nestl glaxosmithkline sonova johnson johnson straumann merck co swiss novartis ubs pfizer zurich insurance sanofi takeda peer set market comparison companies salary assessment pharma peer set major swiss companiesremuneration report roche procedure submitting total board retrospective approval executive remuneration shareholder approval total aggregate bonus amounts corporate annual general meeting executive committee chairman board year annual general meeting agm directors financial year ended shareholders approve total remuneration submitted retrospectively ordinary agm board directors corporate executive separate binding approval committee decided board directors remuneration committee board directors prospective approval respectively board executive aggregate remuneration submitted prospectively agm separate according approval agm roche binding approval period two committed obtaining separate ordinary agms binding shareholder approvals total remuneration paid board directors corporate executive committee follows approval total remuneration annual general meeting financial year financial year agm retrospective c chairman bod c bonus bonus financial year total amount cec corporate executive committee cec including bonus ceo roche group bonus financial year total amount prospective board directors bod including c bod base payremuneration aggregate total remuneration agm agm base payremuneration corporate executive committee cec including ceo roche group cec base pay aggregate total remuneration agm agm ssars base pay rsus stocksettled stock appreciation rights ssars indirect benefits restricted stock units rsus see indirect benefits peer set agm agm agm remuneration components overview remuneration elements remuneration components linked remuneration members board employees performance companys financial directors corporate executive committee performance commercial success thus composed following elements concrete align interests roche employees composition see chart composition shareholders remuneration board directors corporate executive committee lti remuneration components intended sustainably homogenously longterm fixed base salary complemented oriented align managements interest annual variable bonus shortterm incentive shareholders holders nonvoting equity sti perennial remuneration elements securities give participating managers ssars psp see longterm additional incentive achieve value growth incentive lti form longterm total shareholder returns composition remuneration board directors corporate executive committee annual remuneration elements description c bod ceo roche group cec base pay monthly payment q uarterly remuneration see payments bonus annual payment years years cash see blocked nonvoting blocked non equity securities voting equity andor shares securities andor shares pensions etc see perennial remuneration elements stocksettled stock see appreciation rights ssars performance share see years plan psp blocked non voting equity securities andor sharesremuneration report roche variable longterm sti base salary bonus indirect benefits employer contribution lti pensions insurance contributions stocksettled stock roche roche connect appreciation rights tax consulting services remuneration performance share plan expense allowances components others childrens schooling costs foreign tax obligation ahvivalv fixed base pay fixed december end reporting year base pay cash payment determined january following reporting year remuneration position based salary market data leading committee decides bonuses amounts global pharmaceutical companies see footnote payable chairman board members major swiss companies see footnote corporate executive committee respect reflects individuals abilities experience current reporting year based performance performance time pay adjustments likewise aforementioned objectives linked individual performance take account time remuneration committee also decides prevailing market conditions companys form bonuses awarded ie cash payments overall financial situation andor nonvoting equity securities andor shares remuneration committee makes reviews stocksettled stock appreciation rights final decision individual base pay paid ssars longterm chairman board directors members ssars entitle holders benefit financially corporate executive committee increase value roches nonvoting equity remuneration members board securities grant date exercise date ssars granted vest together bonuses variable three years see bonuses annually awarded individual exercised within seven years grant date contributions value creation business year see unexercised ssars lapse meant incentive strive outstanding without compensation since fair value results create new business opportunities ssars calculated grant date using bonus amounts linked group divisional trinomial model american call options core profits sales growth constant exchange rates details see operating profit capital charge opac based core operating profit core earnings per share ssars corporate executive committee nonvoting equity security nes growth constant allocated individually remuneration exchange rates product development pipeline committees discretion addition around diversity employees managers environmental employees received ssars new goals achievement measurable choice mix ssars rsus qualitative individual functional performance regarding changes vesting expiration objectives competitive reasons roche periods composition remuneration disclose individual performance objectives components corporate executive committee members corporate executive committee enlarged corporate executive committee chairman starting see performance share plan psp longterm granted vested recipient psp established periods three three years thereafter resulting nonvoting years based threeyear comparison equity securities andor shares may remain blocked total shareholder return tsr peer ten years new choice mix companies see footnote ssars rsus regarding changes vesting expiration periods respective year psp consists three composition remuneration components overlapping performance cycles new cycle corporate executive committee enlarged starting beginning year cycle corporate executive committee see finishing end year three overlapping performance cycles psp outlook psp psp psp starting subject approval closed december see corresponding changes articles incorporation annual general meeting plans key performance metric award composition remuneration components tsr calculated threemonth moving longterm incentive lti corporate average rate start end executive committee enlarged corporate performance cycle payment psp executive committee change new psp awards determined board directors annual granted end whereby basis acting upon recommendations board directors acting upon recommendations remuneration committee remuneration committee must determine payment ongoing psp psp since psp awards remuneration component end respectively reserved corporate executive lti corporate executive committee committee enlarged corporate executive enlarged corporate executive committee committee however new awards granted complemented restricted stock units see rsus composed ssars rsus based already existing individual longterm incentives corporate target value total lti corporate executive executive committee comprised psp committee members base pay awards ssars approximately measured january year vesting expiration periods aligned ssars rsus restricted stock units rsus longterm see rsu awards allocated individually rsus serve remuneration component around corporate executive committee enlarged eligible roche employees rsus contain corporate executive committee remuneration rights receive nonvoting equity securities andor committees discretion unlike participants shares threeyear vesting period plus value two programmes members corporate adjustment amount equivalent executive committee enlarged corporate sum dividend paid vesting period executive committee choice determining attributable number nonvoting equity mix rsus ssars securities andor shares individual award fouryear cliff vestingremuneration report roche new grant march vesting schedule ssars currently threeyear remaining participants ssars rsus annual vesting also aligned fouryear programmes offered choice three annual vesting schedule new grants combinations determine mix restricted stock units rsus stocksettled stock appreciation innovative changes make roche long rights ssars options used instead ssars term incentive programme attractive enabling countries following options offered roche attract motivate retain best talent keep aligned companys longterm choice choice choice success ssars ssars ssars rsus rsus rsus indirect benefits shown ceo roche group offering level choice empowers participants chairman respectively members engage fully total rewards enables corporate executive committee additionally better understand critical element received indirect benefits payments pension compensation increases value programme funds mgb stiftung der f hoffmannla roche ag positions roche first among peer group fr mitarbeitergewinnbeteiligung als ergn zung provide benefit expiration period der beruflichen vorsorge ie employee profitsharing newly issued ssars extended currently foundation supplementing occupational pension seven years ten years give participants benefits insurances roche connect payments additional three years exercise vested ssars foreign tax obligation tax consulting services vesting schedule newly issued rsus annual expense allowances shown change threeyear cliff vesting fouryear individual members corporate annual vesting year granted rsus executive committee received payments vest become available participants schooling costs children weighting fixedvariable longterm remuneration components target percentage total remuneration chairman board directors corporate executive committee including ceo roche group fixed variable longterm ratio remuneration components relative fixed base pay corporate executive committee ratio variable remuneration components bonuses ssars psp relative value fixed base pay sti variable lti longterm criteria bonus ssars psp individual target value minimum maximum performance criteria group objectives group value development determined value development determined divisional business performance performance plus value performance plus value individual objectives adjustment dividends adjustment dividends considering core profits sales nes grant nesshares grant growth constant exchange group performance tsr rates operating profit relation tsr performance capital charge opac based peer set tsr definition see core operating profit core earnings per share nonvoting equity security nes growth constant exchange rates product development pipeline diversity employees managers environmental goals split group objectives na b individual objectives na na applicable assessed consideration performance competitors macroeconomic development based annual base pay measured january first year cycle details please refer following sections remuneration report see also finance report note roche group consolidated financial statements related parties note financial statements roche holding ltd board executive shareholdings remuneration report roche remuneration board directors resolution approval directors table board remuneration chairman board activities roche paid legally required employers directors members board directors contributions total chf swiss social decided remuneration committees security programmes providing retirement disability discretion taking account market comparisons unemployment benefits ahvivalv members board directors beside legally remuneration form cash payments required contributions separately stated annually tracked market data directors pay chairman board directors leading global pharmaceutical companies see footnote major swiss companies basic remuneration board directors see footnote assisted consultancy excluding chairman remained unchanged pwc since previous year board exception chairman board directors separately submit total aggregate directors bonus form blocked shares bonus chairman board directors dr severin schwan executive member general meeting financial year board members board directors retrospectively binding approval awarded shares nonvoting equity securities ssars maximum amounts total aggregate remuneration board directors period loans credits granted members ordinary general meeting board directors ordinary general meeting tabled previous year general meetings capacity member chugai international prospectively binding approval see council cic chugai pharmaceutical co ltd andr hoffmann received honoraria amount remuneration members amounting total usd chf board directors members board directors advisory service genentech scientific received remuneration additional compensation review board prof dr richard p lifton received form quarterly fixed cash payments shown honoraria amounting total usd remuneration members board chf list members positions committee memberships chairmanships see detidua remuneration members board directors chf additional remuneration additional special basic remuneration committee memberschairs remuneration total remuneration ch franz chairman see total remuneration paid chairman board directors hoffmann vicechairman see j bell j brown p bulcke hauser rp lifton see oeri b poussot schwan see highest total remuneration paid dr severin schwan member corporate executive committee remuneration received primary function ceo roche group reflected total remuneration corporate executive committee c suessmuth dyckerhoff pr voser total exception members presidium chairman vicechairman board members receive chf year committee serve chf year committee chair remuneration serving vicechairman board additionally employer contribution ahvivalv totalling chf including chairman paid form part remuneration detiduaremuneration report roche total remuneration paid chairman form shares blocked ten years payable board directors march put shareholder binding vote chairman dr christoph franz received total ordinary annual general meeting agm remuneration shown remuneration committees bonus proposal adopted chairmans total remuneration contained late respect financial year total remuneration board directors detidua remuneration members board directors chf additional remuneration additional special total basic remuneration committee memberschairs remuneration remuneration ch franz chairman see total remuneration paid chairman board directors hoffmann vicechairman j bell j brown p bulcke hauser since march rp lifton oeri b poussot schwan see highest total remuneration paid dr severin schwan member corporate executive committee remuneration received primary function ceo roche group reflected total remuneration corporate executive committee c suessmuth dyckerhoff pr voser p baschera retired march total exception members presidium chairman vicechairman board members receive chf year committee serve chf year committee chair remuneration serving vicechairman board prorated remuneration period march december prorated remuneration paid period january march additionally employer contribution ahvivalv totalling chf including chairman paid form part remuneration total remuneration paid board board remuneration subject approval directors annual general meeting calendar year members board directors received remuneration including submission chairmans total aggregate bonuses employer contribution social bonus binding vote annual general securities beneficial parts totalling chf meeting chf excluding additional remuneration chairman board employers contribution paid ahvivalv directors includes bonus award chf totalling chf chf form sharesblocked ten years shown form part remuneration table section total remuneration paid chairman board directors board remuneration paid former members directors submit remuneration committees board directors bonus proposal adopted late chairman former member board directors dr franz b board dr christoph franz respect humer received fees amounting total financial year payable march excluding usd chf serving member legally required employers contributions ahviv chugai international council cic chugai alv shareholder binding vote pharmaceutical co ltd ordinary annual general meeting former member board directors william burns received honoraria amounting total usd chf capacity member chugai international council cic chugai pharmaceutical co ltd additional remuneration paid detidua total remuneration paid chairman board directors chf base salary cash bonus subject approval annual general meeting pension fundsmgb insurancesannual expense allowances total form shares blocked years calculation number shares based price date transfer march april respectively approval agm agm respectively calculation value consideration reduction value due blocking period years reduced market value submitted shareholder approval agm approved agm respectively ncluding employer contribution social securities beneficial parts mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits additionally employer contribution ahvivalv chf chf paid form part remuneration detiduaremuneration report roche retrospective approvals chairmans total aggregate bonus chf proposal agm agm agm aggregate amount aggregate amount aggregate amount financial year financial year financial year total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv bonus award form shares blocked years calculation number shares based price date transfer march april april respectively approval agm agm agm respectively calculation value consideration reduction value due blocking period years reduced market value submitted shareholder approval agm approved agm agm respectively submission boards total aggregate dr severin schwans remuneration shown future remuneration binding shareholder vote receives function ceo roche group board directors proposes member corporate executive committee ordinary agm approve board remuneration totalling included part corporate chf excluding legally executive committees total remuneration required employers contributions ahvivalv excluding bonuses period ending ordinary agm prospective approvals boards total aggregate future remuneration chf proposal agm agm agm aggregate amount aggregate amount aggregate amount period period period agm agm agm agm agm agm total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv excluding bonuses reconciliation reported remuneration comparison ordinary agm shareholders approved remuneration ordinary agm actual remuneration amounted members board directors chf excluding legally required employers ordinary agm approved board remuneration contributions ahvivalv excluding bonuses totalling chf excluding legally required employers contributions ahviv alv excluding bonuses period ending ordinary agm prospectively approved total remuneration members board directors comparison actual total payments made chf total remuneration total remuneration total remuneration period period period agm agm agm agm agm agm maximum total remuneration approved agm actual total remuneration paid calculation end period within approved limit calculation end period yes yes excluding legally required employers contributions ahvivalv excluding bonuses security holdings related parties note directors andr hoffmann dr andreas oeri financial statements roche holding ltd members founders families closely significant shareholders addition associated belong contractually bound december december shareholder group pooled voting rights respectively members board directors end group held shares persons closely associated held roche issued shares detailed information shares nonvoting equity securities nes group found finance report note american depositary receipts adrs shown roche group consolidated financial statements table security holdings security holdings shares nes december december nonvoting nonvoting equity close relatives equity close relatives securities security securities security shares nes holdings others shares nes holdings others number number numbertype number number number numbertype number board directors ch franz hoffmann j bell j brown p bulcke hauser nes nes rp lifton adrs adrs oeri b poussot schwan see security holdings see security holdings corporate executive committee corporate executive committee c suessmuth dyckerhoff pr voser total nes adrs nes adrs shares held shareholder group pooled voting rights listed jointly held close relative roches adr american depositary receipt listed otcqx wwwotcmarketscomstockrhhbyquote international premier symbol rhhby isin us traded usd eight adrs represent one underlying nesremuneration report roche remuneration corporate executive committee resolution approval members corporate executive remuneration members corporate committee received remuneration work executive committee decided remuneration shown amount remuneration committees discretion taking account market ceo roche group dr severin schwan comparisons explained detail previous year board payments base pay bonus ssars rsus indirect directors separately submit total aggregate benefits employer contibutions pension bonuses corporate executive committee funds mgb roche connect expense allowances general meeting financial year etc dr michael heuer appointed retrospectively binding approval ceo roche diagnostics october included aggregated total remuneration maximum amounts total aggregate corporate executive committee see remuneration corporate executive committee period ordinary general meeting highest total remuneration paid ordinary general meeting dr severin schwan member corporate tabled previous year general executive committee meetings prospectively binding approval see dr severin schwan executive member board directors received remuneration primary amount remuneration members function ceo roche group reflected corporate executive committee highest total remuneration paid member general provisions assigning authority decisions corporate executive committee see corporate executive committee remuneration included total amount paid corporate remuneration committee board executive committee see total remuneration directors outlined remuneration paid members corporate executive decision process approval framework committee highest total remuneration paid dr severin schwan member corporate executive committee chf base salary ssars pension fundsmgb insurances roche connect bonus subject approval total aggregate bonuses corporate executive committee annual general meeting blocked shares psp payments incl expense allowancefor tax consulting services total calculation value nonvoting equity securitiesshares consideration reduction value due blocking period years reduced market value including employer contribution social securities beneficial parts detailed calculation remuneration see annual report number ssars grant value according trinomial model american call options chf trinomial model american call options value described stocksettled stock appreciation rights ssars members corporate executive committee number ssars grant value according trinomial model american call options chf trinomial model american call options value described stocksettled stock appreciation rights ssars members corporate executive committee mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits shares blocked years calculation number shares based share price date transfer march approval agm target number nonvoting equity securities psp nonvoting equity securities multiplied per nonvoting equity securities price averaged three months october december prior start performance cycle chf nonvoting equity security target number nonvoting equity securities psp nonvoting equity securities multiplied per nonvoting equity securities price averaged three months october december prior start performance cycle chf nonvoting equity security includes annual expense allowance chf payments tax consulting services chf chf anniversary payment chf additionally employer contribution ahvivalv chf chf paid form part remuneration base pay members corporate executive committee base pay chf r diggelmann retired corporate executive committee end september hippe g keller oday c wilbur total prorated remuneration period january september detidua detidua base pay dr michael heuer included aggregated total remuneration corporate executive committee see remuneration report roche bonuses members corporate executive committee see total aggregate executive committee amount bonuses brought forward remuneration committee board directors binding vote annual general meeting determined corporate executive committee members bonuses based performance except dr severin schwan members agreed objectives dr michael heuer corporate executive committee receive regular bonus chf bonus bonus cash payment due interim function additional chf total march dr severin schwan receive bonus chf million proposed included form roche shares blocked ten years aggregated total remuneration corporate see bonus payment due march bonus chf subject approval total aggregate bonuses corporate executive committee annual general meeting r diggelmann retired corporate executive committee end september hippe g keller oday c wilbur total stocksettled stock appreciation rights options trinomial model effective method ssars members corporate valuation american call options considers executive committee possibility exercising option time prior ssars shown ssars table maturity called american option compared entitle holders benefit financially european option allows exercise increase value roches nonvoting equity maturity date securities nes grant date exercise date strike price ssars numbers ssars strike prices expiry terms multiyear plan closing price dates grant values ssars shown roche nes grant date ssars vest three ssars table numbers years grant date vested ssars ssars calculated time issue exercised converted nes within seven years entered values table pages grant date unexercised ssars lapse without ssars granted dr michael heuer subject compensation yearly vesting shown ssars table fair value included aggregated fair value ssars calculated grant total remuneration corporate executive date using trinomial model american call committee see information trinomial model american call options please refer boyle phelim p lattice framework options pricing two state variables journal financial quantitative analysis volume issue mar rochecomtrinomialmodelpdf see strike prices table ssars detidua stocksettled stock appreciation rights ssars chf ssars ssars r diggelmann retired corporate executive committee end september hippe g keller oday c wilbur total grant ssars grant value chf per ssar price chf expiry date performance share plan psp sum dividend paid vesting members corporate executive committee period attributable number nonvoting psp consists overlapping threeyear equity securities shares individual per formance cycles new cycle beginning award granted requires roche year thus three cycles progress securities perform well better psp psp psp peer set event investment whereas psp closed december roche securities underperforms average return none targeted shares awarded delivered peer companies fewer nes shares awarded provisions plan number nonvoting equity securities nes shares nes reserved plan reserved participants cycle members corporate executive committee number securities actually awarded depend shown table whether extent investment roche board directors decide actual level securities shares nes outperforms average nes shares cash equivalent awards psp return investment securities issued set cycles close peer companies comparisons based financial years respectively aim securities market prices dividend yields ie psp provide incentive participants total shareholder return tsr reduce achieve longterm value growth due roland effect shortterm market fluctuations security diggelmanns daniel odays resignations prices averaged three months october potential awards reduced december prior start performance cycle three months october december dr michael heuer participating psp end cycle programme roche securities perform better average end psp cycle based peer set board directors elect threemonth average distributed dividends increase nes shares award maximum totalling chf billion chf billion award double originallevel reserved target chf billion chf billion number nes shares according psp plus according terms plan participants value adjustment amount equivalent received none originally targeted shares see footnote detiduaremuneration report roche restricted stock units members roche connect voluntary stock purchase plan corporate executive committee offering employees opportunity buy roche member corporate nonvoting equity securities nes amount executive committee dr michael heuer received equal annual salary discount rsus appointment ceo roche nes purchased plan subject diagnostics see holding period four years switzerland indirect benefits members addition members corporate executive corporate executive committee committee received annual expense allowances employer contributions made social security members payments foreign tax obligations schemes pension plans groupwide employee tax consulting services shown table stock purchase plan roche connect respect members corporate executive committee shown indirect benefits employer contributions table employer contributions shown table detidua performance share plan psp fair value grant fair value grant per nonvoting per nonvoting equity security equity security nes nes prices nes nes prices averaged averaged three months fair value three months fair value target number october target number target number october target number nonvoting december nonvoting nonvoting december nonvoting equity securities prior start equity securities equity securities prior start equity securities nes performance nes nes performance nes psp cycle psp psp psp cycle psp psp number value chf value chf number value chf value chf r diggelmann hippe ga keller oday c wilbur total calculation value nonvoting equity securities consideration reduction value due blocking period years reduced market value calculation value nonvoting equity securities consideration reduction value due blocking period years reduced market value retired corporate executive committee end september detidua detidua indirect benefits employer contributions chf pension payments pension payments funds annual taxtax funds annual taxtax mgb expense roche consulting mgb expense roche consulting insurances allowances connect services insurances allowances connect services r diggelmann hippe g keller oday c wilbur total including employer contribution social securities beneficial parts r etired corporate executive committee end september mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits payments employer contibutions indirect benefits remuneration former members pension funds mgb roche connect expense corporate executive committee allowances etc dr michael heuer included pensions totalling chf aggregated total remuneration corporate chf paid former corporate executive committee see executive committee members remuneration loans members total remuneration paid members corporate executive committee corporate executive committee based contractual obligations roche paid calendar year members individual members corporate executive corporate executive committee received committee childrens schooling costs remuneration including bonuses employer totalling chf chf contribution social securities beneficial parts payments dr michael heuer ceo aforementioned additional payments included roche diagnostics totalling chf total remuneration members corporate chf excluding additional executive committee employers contribution paid ahvivalv totalling chf chf loans credits granted form part remuneration members corporate executive committee additional remuneration maximum regular period notice members mentioned payments paid current former corporate executive committee months members corporate executive committee changeofcontrol clauses employment contracts detidua detiduaremuneration report roche executive remuneration subject approval blocked ten years members annual general meeting corporate executive committee cash payment see totalling chf respect submission executive total aggregate financial year chf bonuses binding vote annual excluding legally required employers contributions general meeting ahvivalv submit proposed total board directors proposes awarding members amount ordinary annual general meeting corporate executive committee bonuses agm binding vote dr severin schwan form roche shares retrospective approvals members executive committees total aggregate bonuses chf proposal agm agm agm aggregate amount aggregate amount aggregate amount financial year financial year financial year total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv submission executive total future aggregate incentives ssars calculated grant value without remuneration binding shareholder vote considering reductions value due blocking periods board directors proposes applicable rsus see calculated ordinary agm approves remuneration time reservation nonvoting equity securities corporate executive committee totalling shares without considering reductions value due chf excluding legally required blocking periods contributions pension benefits employers contributions ahvivalv excluding legally required employers contributions excluding bonuses period ending ahvivalv well contributions expenses ordinary agm payments foreign tax obligations tax consulting services roche connect amount executive total future aggregate remuneration composed base pay longterm prospective approvals members executive committees total future aggregate remuneration chf proposal agm agm agm aggregate amount aggregate amount aggregate amount period period period agm agm agm agm agm agm total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv excluding bonuses reconciliation reported remuneration excluding bonuses period ending shareholders prospectively approved ordinary agm remuneration members corporate executive committee comparison ordinary agm ordinary agm approved remuneration ordinary agm remuneration amounted corporate executive committee totalling chf excluding legally required employers chf excluding legally required contributions ahvivalv excluding bonuses employers contributions ahvivalv psp assumption maximum value prospectively approved total remuneration members executive committee comparison actual total remuneration effected chf amount period amount period amount period agm agm agm agm agm agm maximum total remuneration prospectively approved agm total remuneration calculated end calculation end corresponding agmagm period period agm agm actual total remuneration realised corresponding agmagm period based calculation end calculation end actual amount calculated restrospectively end end end corresponding psp cycle psp cycle psp cycle within approved limit calculation end period calculation end period yes additional amount paid new members corporate executive committee approval agm within approved total amount excluding legally required employers contributions ahvivalv excluding bonuses including assumption amount maximum possible award sharesnonvoting equity securities corresponding psp cycle due award shares psp cycle originally included calculation maximum possible award amount total remuneration period agm agm reduced chf remuneration report roche clawback according regulations psp programme addition applicable statutory provisions originally targeted awarded nes shares roches longterm incentive plans include option shall lapse without compensation upon notice partially reclaim distributed compensation termination employment given reason result special circumstances clawback redundancy disability retirement employee voluntarily serves notice guidelines security holdings termination employment ssars see board directors decided ceo rsus see unvested date roche group cec members must acquire termination employment lapse immediately shares andor nes equivalent two annual base without compensation salaries ceo roche group since equivalent five annual base salaries one annual base salary upon termination employment result respectively end retain serious misconduct ssars rsus granted holdings long serve cec outstanding whether vested unvested shall lapse exception cristina wilbur joined immediately without compensation according corporate executive committee ssars plan rules serious misconduct must fulfil requirement end participant may include inter alia members corporate executive committee activity leading serious disciplinary action fulfil requirement repeated willful failure perform duties reasonably assigned roche security holdings violation law public regulation december december commission crime respectively members cec persons gross negligence willful misconduct employment closely associated held securities shown engaging conduct bringing disgrace disrepute tables shares nonvoting equity securities roche andor subsidiaries nesand ssars violation roches directives guidelines relating business conduct type security value acquired ceo roche group shares andor nes annual base salary members corporate executive committee shares andor nes annual base salary shares nonvoting equity securities nes december december close relatives close relatives shares nes security holdings shares nes security holdings number number numbertype number number numbertype corporate executive committee shares nes shares schwan hippe ga keller oday c wilbur heuer na na na total na applicable excluding rsus ssars number ssars held december corporate executive committee schwan hippe g keller oday ca wilbur heuer total price chf market price per nes december chf expiry date grant value per ssar chf since trinomial model american call options v alues according corresponding annual reports e xcluding closerelatives ssars price chf expiry date grant value per ssar chf holdings totalstatutory auditors report roche general meeting roche holding ltd basel audited accompanying remuneration audit involves performing procedures obtain report roche holding ltd year ended audit evidence disclosures made december audit limited remuneration report regard compensation information according articles ordinance loans credits accordance articles excessive compensation stock exchange ordinance procedures selected depend listed companies ordinance contained auditors judgement including assessment sections marked audited grey line including risks material misstatements remuneration respective footnotes pages report whether due fraud error audit also remuneration report includes evaluating reasonableness methods applied value components remuneration well assessing overall presentation responsibility board directors remuneration report board directors responsible preparation overall fair presentation believe audit evidence obtained remuneration report accordance swiss law sufficient appropriate provide basis ordinance board directors also opinion responsible designing remuneration system defining individual remuneration packages opinion opinion remuneration report year auditors responsibility ended december roche holding ltd responsibility express opinion complies swiss law articles accompanying remuneration report conducted ordinance audit accordance swiss auditing standards standards require comply ethical requirements plan perform audit obtain reasonable assurance whether remuneration report complies swiss law articles ordinance kpmg ag mark baillache marc ziegler licensed audit expert licensed audit expert auditor charge basel january kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firms affiliated kpmg international cooperative kpmg international swiss legal entity rights reserved independent assurance report roche sustainability reporting corporate governance sustainability committee chemical industry council cefic gri standards roche holding ag basel published october global reporting initiative gri roche group internal corporate reporting manual engaged perform assurance procedures provide sustainability reporting guidanceeconomic performance limited assurance aspects sustainability issued june reporting roche holding ag basel consolidated roche materiality determination process corporate level subsidiaries roche included annual report report based gri standards published october global reporting initiative gri scope subject matter defined guidelines people contributions limited assurance engagement focused following data key figures sustainability risks opportunities information disclosed sustainability reporting roche internally gathered collated aggregated year ended december management reporting processes respect inherent limitations sustainability reporting material aspects accuracy completeness sustainability indicators preparation safety security health environmental subject inherent limitations given nature methods protection contributions people key figures well determining calculating estimating data assurance related control environment relation data report therefore read connection roches internal aggregation key figures guidelines definitions procedures reporting materiality determination process roche group level sustainability performance according requirements gri standards disclosed report roches responsibilities design sustainability risks opportunities roche corporate governance sustainability committee determination process based roche corporatelevel activities responsible subject matter criteria well disclosed paragraph risk management selection preparation presentation selected report information accordance criteria responsibility people key figures disclosed pages report includes design implementation maintenance related key figures including greenhouse gas emissions scope internal control relevant reporting process free scope resulting business travel compressed air material misstatement whether due fraud error liquid nitrogen waste tables graphs pages report responsibility figures roche group level relation contributions responsibility form independent opinion based donations disclosed report limited assurance procedures whether anything come attention indicate identified sustainability information carried work data reported prior selected contained report stated material reporting periods performed work respect respects accordance reporting criteria projections targets planned performed procedures accordance criteria international standard assurance engagements isae management reporting processes respect revised assurance engagements audits reviews sustainability reporting key figures prepared roche historical financial information respect greenhouse based internal policies procedures set forth gas emissions international standard assurance following engagements isae assurance engagements greenhouse roche group internal sustainability reporting guidelines gas statements issued international auditing assurance based responsible care health safety environmental standards board standards require plan perform protection reporting guidelines published european assurance engagement obtain limited assurance theindependent assurance report roche identified sustainability information prepared material reviewing relevant documentation sample basis including aspects accordance roches internal policies procedures roche group sustainability policies management reporting structures documentation limited assurance engagement isae revised reviewing principles roche materiality process isae substantially less scope reasonable assurance providing definition development adherence engagement relation risk assessment procedures gris environmental social economic reporting requirements including understanding internal control procedures addressing soundness identification process performed response assessed risks consequently determination impacted stakeholders peer competition nature timing extent procedures gathering sufficient review integration relevant regulatory requirements integration appropriate evidence deliberately limited relative reasonable key organisational values objectives report prioritisation assurance engagement therefore less assurance obtained material aspects limited assurance engagement reasonable inspecting integration sustainability risks assurance engagement procedures selected depend opportunities group risk management process assurance practitioners judgement adherence internal guidelines assessment processes data consolidation independence quality control reviewing management sustainability reporting complied independence ethical processes contributions people key figures requirements code ethics professional accountants assessing consolidation process data roche group level issued international ethics standards board accountants founded fundamental principles integrity objectivity conducted work data outlined professional competence due care confidentiality subject matter defined believe evidence professional behaviour obtained sufficient appropriate provide basis assurance conclusion firm applies international standard quality control accordingly maintains comprehensive system quality control conclusion including documented policies procedures regarding compliance based work performed described report ethical requirements professional standards applicable identified roche sustainability reporting nothing come legal regulatory requirements attention causing us believe material respects roche group internal sustainability reporting guidelines summary work performed based gri standards well cefic guidelines assurance procedures included amongst others following applied work roche materiality determination process corporate level review application roche group guidelines disclosed adhere principles guiding factors reviewing application roche group internal corporate eg soundness stakeholder determination peer review relevance sustainability contributions guidelines regulatory environment integration key organisational values site visits management inquiry objectives defined gri standards visiting selected sites roches pharmaceuticals diagnostics design sustainability risks opportunities divisions usa germany greece colombia italy determination process corporate level disclosed selection based quantitative qualitative criteria function designed interviewing personnel responsible internal sustainability internal reporting processes collect aggregate reporting data collection sites visited people contributions data functioning designed roche group level determine understanding application provide appropriate basis disclosure roches internal sustainability guidelines sustainability information mentioned subject matter assessment key figures disclosed within sustainability reporting roche annual performing tests sample basis evidence supporting selected report stated accordance reporting criteria contributions people key figures eg roche accident rate energy consumption greenhouse gas emissions related energy consumption water waste contributions public policy pricewaterhousecoopers ag stakeholders representation women key leadership roles concerning completeness accuracy adequacy consistency christophe bourgoin fabienne fricker review documentation analysis relevant policies principles zurich january modern technologies digitalisation sophisticated data analysis support scientists roche research product development picture shows scientist preparing sample analysis key dates published f hoffmannla roche ltd annual general meeting group communications march basel switzerland tel firstquarter sales wwwrochecom april orderdownload publications halfyear results internet rochecompublications july email baselwarehouseservicesrochecom fax nine months sales october media relations tel email mediarelationsrochecom investor relations tel email investorrelationsrochecom corporate sustainability committee tel email corporatesustainabilityrochecomimprint roche cautionary statement regarding forwardlooking statement regarding earnings per share growth statements profit forecast interpreted annual report contains certain forwardlooking mean roches earnings earnings per share statements forwardlooking statements may subsequent period necessarily identified words believes expects match exceed historical published earnings anticipates projects intends seeks earnings per share roche estimates future similar expressions discussion among things strategy goals trademarks legally protected plans intentions various factors may cause actual results differ materially future links thirdparty pages provided convenience reflected forwardlooking statements contained express opinion content annual report among others pricing thirdparty pages expressly disclaim product initiatives competitors legislative liability thirdparty information use regulatory developments economic conditions delay inability obtaining regulatory approvals bringing products market fluctuations roche annual report published german currency exchange rates general financial market english conditions uncertainties discovery development marketing new products new reporting consists actual annual report uses existing products including without limitation finance report contains annual negative results clinical trials research projects financial statements consolidated financial unexpected side effects pipeline marketed statements regards content management products increased government pricing pressures report per articles incorporation consists interruptions production loss inability aforementioned reports exception obtain adequate protection intellectual property remuneration report rights litigation loss key executives employees adverse publicity printed nonchlorine bleached fsccertified paper news coveragewe share one purposedoing patients need nextwe believe urgent deliver medical solutions right noweven develop innovations future passionate transforming patients lives courageous decision action believe good business means better world come work day commit scientific rigour unassailable ethics access medical innovations today build better tomorrow proud many working one across functions across companies across world roche contents believe urgent deliver medical overview solutions right noweven develop chu ar rt mra ne g sy shareholder letter innovations future passionate ceos shareholder letter transforming patients lives business performance group performance courageous decision action phia ag rmno ct eic us ip ce ar lsfo pr em rfa rc ance believe good business means science innovation better world dd ee vn et li ofy pi ng g die ad gi nc oa sl tn ice e ted sts health apps come work day access healthcare joining forces make difference commit scientific rigour enabling sustainable healthcare funding unassailable ethics access medical people aannnnuuaall rreeppoorrtt learning leadership development innovations today worldclass talent shaping future build better tomorrow environment reducing energy water consumption proud reducing emissions air water many working c pt ar reo tn nm g et rh inem gn tn ou g n lo aci kat el ac dme iffmn erug en na ct eig ese ment one across functions across companies across world enn sut ing gr bi ut siy ne si sn co nb tiu nus iti yness developing lasting partnerships corporate governance roche b co oa rr pd ro af e eir xe ec cto ur tis committee remuneration report principles remuneration components e roche annual report f hoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom journey recovery woman shown cover roche annual report year appeared cover report well last year f hoffmannla roche ltd basel switzerland midst receiving treatment breast cancer trademarks legally protected wwwrochecom photographed came powerfully cover year later enjoying life p e n innovation p r n e r introduced ocrevus medicine people autism collaboration partners treatment two forms multiple spectrum disorder phase iii authorities developing sclerosis ocrevus demonstrated studies common nextgeneration diagnostic tests superior efficacy reducing neurodevelopmental condition medicines aim relapses slowing worsening characterised difficulties diagnosing treating multi disability caused ms regarding social interaction drugresistant bacterial infections cover shows woman diagnosed cancer